• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • Composition of Methods (COM)
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Grok 4 aids Exit
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

2.0 LPBI Group News

2026

UPDATED on 1/12/2026

Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry

Curator: Grok 4.1

https://pharmaceuticalintelligence.com/2026/01/11/aviva-lev-ari-phd-rn-biography-grokepedia-entry/

 

Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality

Curator: Grok 4.1

https://pharmaceuticalintelligence.com/2026/01/12/evolving-lpbi-groups-portfolio-of-intellectual-properties-ip-from-2021-vision-to-2026-reality/

UPDATED on 1/10/2026

Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com

Collection Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2026/01/10/collection-of-aviva-lev-ari-phd-rn-scientific-articles-on-pulse-on-linkedin-com/

 

Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter

Article selection: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2026/01/10/article-selection-from-collection-of-aviva-lev-ari-phd-rn-scientific-articles-on-pulse-on-linkedin-com-for-training-small-language-models-slms-in-domain-aware-content-of-medical-pharmaceutical-l/

 

List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2026/01/10/list-of-articles-included-in-the-article-selection-from-collection-of-aviva-lev-ari-phd-rn-scientific-articles-on-pulse-on-linkedin-com-for-training-small-language-models-slms-in-domain-aware-cont/

 

UPDATED on 1/6/2026

2026 Grok Multimodal Causal Reasoning on Proprietary Cardiovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage

Authors:

  • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
  • Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2026/01/06/2026-grok-multimodal-causal-reasoning-on-proprietary-cardiovascular-corpus-from-2021-wolfram-nlp-baseline-to-thousands-of-novel-relationships-a-second-head-to-head-validation-of-lpbi/

 

UPDATED on 1/6/2026

Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods

Authors:

  • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
  • Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2026/01/06/workflow-for-dynamic-linkage-and-transition-between-two-authoring-systems-lpbi-groups-wordpress-com-multi-authors-authoring-system-and-microsoft-powerpoint-product-for-slide-show-presentation-par/

2025

UPDATED on 12/30/2025

Marquee Followers 80% Healthcare Persons and Institutions for @AVIVA1950 and @Pharma_BI

Reporter: Aviva Lev-Ari, PhD, RN
 
https://pharmaceuticalintelligence.com/2025/12/08/marquee-followers-80-healthcare-persons-and-institutions-for-aviva1950-and-pharma_bi/

UPDATED on 12/27/2025

Composition of Methods (COM) – IP Asset Class IV

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/composition-of-methods-com/

UPDATED on 12/19/2025

AI in Health, The Voice of Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/ai-health-voice-aviva-lev-ari-phd-rn-aviva-lev-ari-phd-rn-xgqie

 

UPDATED on 12/15/2025

2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle”

Authors:

  • Stephen J. Williams, PhD (Chief Scientific Officer, LPBI Group)
  • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief Journal and BioMed e-Series, LPBI Group)
  • Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2025/12/15/2025-grok-4-1-causal-reasoning-multimodal-on-identical-proprietary-oncology-corpus-from-673-to-5312-novel-biomedical-relationships-a-direct-head-to-head-comparison-with-2021-static-nlp-new-foun/

UPDATED on 12/9/2025

AI and Health Day @AIW25, AI Week, December 9 – December 11, 2025, 8:30 AM IST – 6PM IST, Tel Aviv University

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2025/12/01/ai-and-health-day-aiw25-ai-week-december-9-december-11-2025-tel-aviv-university/

UPDATED on 11/22/2025

Journal

  • AI Initiatives in Big Pharma @Grok prompt & Proprietary Training Data and Inference by LPBI Group’s IP Asset Class I: PharmaceuticalIntelligence.com Journal, 2.5MM Views, 6,250 Scientific articles and Live Ontology

https://pharmaceuticalintelligence.com/2025/11/22/ai-initiatives-in-big-pharma-grog-prompt-proprietary-data-training-and-inference-by-lpbi-groups-ip-asset-class-i-pharmaceuticalintelligence-com-journal-2-5mm-views-6250-scientific-article/

 

e-Books

  • AI Initiatives in Big Pharma @Grok prompt & Proprietary Training Data and Inference by LPBI Group’s IP Asset Class II: 48 e-Books: English Edition & Spanish Edition. 152,000 pages downloaded under pay-per-view

https://pharmaceuticalintelligence.com/2025/11/22/ai-initiatives-in-big-pharma-grog-prompt-proprietary-training-data-and-inference-by-lpbi-groups-ip-asset-class-ii-48-e-books-english-edition-spanish-edition-152000/

 

e-Proceedings

  • AI Initiatives in Big Pharma @Grok prompt & Proprietary Training Data and Inference by LPBI Group’s IP Asset Class III: 100 e-Proceedings and 50 Tweet Collections of Top Biotech and Medical Global Conferences, 2013-2025

https://pharmaceuticalintelligence.com/2025/11/22/ai-initiatives-in-big-pharma-grog-prompt-proprietary-training-data-and-inference-by-lpbi-groups-ip-asset-class-iii-100-e-proceedings-and-50-tweet-collections-of-top-biotech/

 

Biological Images – Art Galley in the WordPress Cloud, privileged access via Dashboard

  • AI Initiatives in Big Pharma @Grok prompt & Proprietary Training Data and Inference by LPBI Group’s IP Asset Class V: 7,500 Biological Images in LPBI Group’s Digital Art Media Gallery, as Prior Art

https://pharmaceuticalintelligence.com/2025/11/22/ai-initiatives-in-big-pharma-grog-prompt-proprietary-training-data-and-inference-by-lpbi-groups-ip-asset-class-v-7500-biological-images-in-lpbi-groups-digital-art/

 

Audio Podcasts

  • AI Initiatives in Big Pharma @Grok prompt & Proprietary Training Data and Inference by LPBI Group’s IP Asset Class X: +300 Audio Podcasts Library: Interviews with Scientific Leaders

https://pharmaceuticalintelligence.com/2025/11/22/ai-initiatives-in-big-pharma-grog-prompt-proprietary-training-data-and-inference-by-lpbi-groups-ip-asset-class-x-300-audio-podcasts-library-interviews-with-scientific-leaders/

 

UPDATED on 11/17/2025

  • Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma

https://pharmaceuticalintelligence.com/2025/11/15/authentic-relevance-of-lpbi-groups-portfolio-of-ip-as-proprietary-training-data-corpus-for-ai-initiatives-at-big-pharma/

UPDATED on 10/1/2025

Updated on 3/7/2024

The Portfolio of IP Digital Assets consists of the following ten (10) Asset Classes representing +7GB of data:

  • On 3/7/2024 – Journal, 2.30MM views, 6,200 articles, ~70% curations
  • On 10/1/2025 – Journal, 2.46MM views, 6,247 articles, ~70% curation
 
  • 48 e-Books: English-language Edition, Spanish-language Edition and five e-Series bundles for each language

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss

  1. 100 e-Proceedings & 50 Tweet collections of Biotech and Medical Conferences
  2. +8,000 biological Images
  3. +300 Audio Podcasts Library – Biological Sciences Discoveries in the 21st Century
  4. +9,300 subscribers to Pharmaceutical Intelligence

https://pharmaceuticalintelligence.com/

  1. Royalties for 155,000-page downloads
  2. Human Capital contributors Bio for 1,2,3,4,5, above
  3. Intangibles assets representing unparalleled e-Reputation of the Intellectual Property created

https://pharmaceuticalintelligence.com/intangibles-cim/Healthcare

 

UPDATED on 8/22/2025

In the Artificial Intelligence (AI) ERA

  1. We pioneered since 2021, applications of AI: Machine Learning (ML) and Natural Language Processing (NLP) for Medical Text analysis on our own content. We published two books with the results of AI algorithms. We teamed up with Linguamatics, now IQVIA for application of their proprietary NLP on 30 articles of ours with outstanding results [Our content was the Training Data rather than using PubMed articles as Training Data]
  2. We explained that AI ERA is moving very fast since (a) ChatGPT launched on 11/2024, (b) DeepSeek on 2/2025, (c) GPT 5 on 8/2025, and (d) Grok 4 & Imagine on 8/2025
  3. We explained that LPBI Group’s IP Portfolio needs to be positioned as TRAINING DATA for AI Modeling in the Healthcare domain as we published in the article

Mission: Design of an Artificial Intelligence [AI-built] Healthcare Foundation Model driven by and derived from Medical Expert Content generated by LPBI Group’s Experts, Authors, Writers (EAWs) used as Training Data for the Model

https://pharmaceuticalintelligence.com/healthcare-foundation-model/

  • Meaning that Scientific Publishers are less important as a Targeted sector to find an acquirer for the IP Portfolio
  • However, IT Companies with Healthcare Applications using AI, i.e., Oracle, Microsoft, Apple, Amazon, Google, NVIDIA are MOST important

We have also produced the article

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director – INTERACTIVE CHAT with Grok, created by xAI

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

Respectively, 
 
• the valuation of the Portfolio is much higher if positioned as 
Training Data vs. as an Archive or a Live Repository of Expert Clinical Interpretations codified in the following five Digital IP ASSETS CLASSES: 
 
• IP Asset Class I: Journal: PharmaceuticalIntelligence.com
6,250 scientific articles (70% curations, creative expert opinions.  30% scientific reports). 
2.4MM Views, equivalent of $50MM if downloading an article is paid market rate of $30.

• IP Asset Class II: 48 e-Books: English Edition & Spanish Edition. 
155,000 pages downloaded under pay-per-view. The largest number of downloads for one e-Publisher (LPBI)
https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
 
• IP Asset Class III: 100 e-Proceedings and 50 Tweet Collections of Top Biotech and Medical Global Conferences, 2013-2025
https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/
 
• IP Asset Class V: 7,500 Biological Images in our Digital Art Media Gallery, as prior art
 
• IP Asset Class X: +300 Audio Podcasts: Interviews with Scientific Leaders
https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/
 
BECAUSE THE ABOVE ASSETS ARE DIGITAL ASSETS they are ready for use as TRAINING DATA for AI Foundation Models in HealthCare.
 
The DATA IS
 
  1. Privately-held not like PubMed in the Public Domain already used and exhausted by all AI companies
  2. We are Debt FREE
  3. Nine Giga Bytes of Digital Data is in the Cloud: Journal and the rest IP Assets are on the Cloud of WordPress.com
  4. All 48 published books are on Amazon.com
  5. Royalties are deposited every 90 days by Amazon to LPBI Group’s Citizens Bank Account in Newton, MA
3, 4, 5, above make Transfer of Ownership an easy act.
 
In addition, other five IP assets include the following:
 
• IP Asset Class VIII: 18,000 Subscribers to the Journal of 6,250 articles. Journal Ontology is extremely valuable as OM (Ontology Method) for LLM, ML, NLP
 
• IP Asset Class IV: Composition of Methods: SOP on How create a Curation, How to Create an electronic Table of Content (eTOC), work flows for e-Proceedings and many more
https://pharmaceuticalintelligence.com/sop-web-stat/
 
• IP Asset Class VII: Royalties paid for pages downloaded from e-Books
 
• IP Asset Class VI: Bios of Experts as Content Creators
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
 
• IP Asset Class IX: INTANGIBLES: e-Reputation: +1,200 Endorsements, Testimonials, Notable followers on X.com: Editor-in-Chief Journal American Medical Association (JAMA), Broad Institute @MIT, Big Pharma, 500 CEOs of them 300 in Biotech are 1st connection on LinkedIn, and more indicators 
https://pharmaceuticalintelligence.com/intangibles-cim/

 

UPDATED on 6/3/2025

Multimodal Healthcare Foundation Model

Mission: Design of an Artificial Intelligence [AI-built] Healthcare Foundation Model driven by and derived from Medical Expert Content generated by LPBI Group’s Experts, Authors, Writers (EAWs) used as Training Data for the Model

Multimodal Healthcare Foundation Model

 

Updated on 5/16/2025

In the Artificial Intelligence (AI) ERA

  • Multimodal Healthcare Foundation Model

https://pharmaceuticalintelligence.com/healthcare-foundation-model/

 

  • LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

 

For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

https://pharmaceuticalintelligence.com/2025/04/29/show-thinking-by-ai-deep-research-the-ai-biography-description-of-aviva-lev-ari-phd-rn-founder-of-pharmaceuticalintelligence-com-by-perplexity-ai-and-by-googles-gemini-2/

Statistics Updated

  • Portfolio of IP Assets – will be updated Online this week

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

>>> IP Asset Class VIII – 5/15/2025 – 18,000 subscribers

>>> IP Asset Class VII – 5/15/2025 – 151,050 page downloads from e-Books

[17 e-Books English Edition, 19 e-Books Spanish Edition]

>>> IP Asset Class I – 5/16/2025 – Journal [On 5/16/2025 All-time stats] http://pharmaceuticalintelligence.com 

Views – 2,390,102

Visitors – 1,508,829

Scientific articles (Posts) – 6,233

 

Updated on 5/16/2025

CLAIMERS by LPBI Group:

  • 1.0 LPBI Group, 4/2012 to 12/2020 was an electronic Scientific Publisher who had perfected the Curation methodology and published e-Books in 5 specialties of Medicine

For 1.0 LPBI Group’s Portfolio of TEN IP digital assets we are targeting our CONTENT for 12 Verticals:

Twelve Economic Segments for LPBI Group’s IP Portfolio of Digital IP Assets: Where to prospect for potential Strategic Acquirers for the Transfer of Ownership. These economic segments include the following:

  1.     Holding Companies, Investment Bankers and Private Equity
  2.     Information Technology Companies – Health Care
  3.     Scientific Publishers
  4.     Big Pharma
  5.     Internet Health Care Media & Digital Health
  6.     Online Education
  7.     Health Insurance Companies & HMOs
  8.     Medical and Pharma Associations
  9.     Medical Education
  10.     Information Syndicators
  11.     Global Biotech & Pharmaceutical Conference Organizer
  12.     CRO & CRA

PLEASE EXPLORE FOR US THE FOLLOWING Companies by Name:

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

 

  • 2.0 LPBI Group, 2021 – 2026

For 2.0 LPBI Group’s IP in the ERA of AI – we are targeting our OWN CONTENT for AI applications in Life Sciences, Medicine, Healthcare and Pharmaceutical, as explained in:

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/ 

For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

https://pharmaceuticalintelligence.com/2025/04/29/show-thinking-by-ai-deep-research-the-ai-biography-description-of-aviva-lev-ari-phd-rn-founder-of-pharmaceuticalintelligence-com-by-perplexity-ai-and-by-googles-gemini-2/

 

  • Looking to the future, The future looks bright, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.

 

  • We are targeting our OWN CONTENT for AI applications. We do NOT USE Electronic Medical/Health Records of Patients with AI like Digital Health domains.
  • Our TEXT and IMAGES do not have the problem of Clean data !!!!!!!!!
  • We published Expert interpretations of scientific findings published in peer reviewed sources.
  • We are the LARGEST privately held repository of curations.
  • Aviva’s multimedia approach to scientific communication is highlighted by the inclusion of (a) 7,074 biological images, (b) 302 podcasts, (c) over 100 e-proceedings for biotech and medical conferences, and more than 50 tweet collections.
  • These resources have enriched the learning experience for professionals worldwide, making complex scientific concepts more accessible and engaging.

We are targeting OUR OWN CONTENT for AI applications in the following Verticals:

  •       Information Technology Companies – Health Care
  •       Scientific Publishers
  •       Big Pharma Drug Discovery
  •       Online & Medical Education
  •       Medical and Pharma Associations
  •       CRO & CRA

PLEASE EXPLORE FOR US THE FOLLOWING AI Companies by Name:

  • @SophontAI
  • Isomorphic Lab – Max Jaderberg
  • Insitro – Daphen Kolller
  • Insilico Medicine
  • Apheris.com –  Consortium Group of PHARMA sharing proterin structure using AI

 

Updated on 4/30/2025

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

https://pharmaceuticalintelligence.com/2025/04/29/show-thinking-by-ai-deep-research-the-ai-biography-description-of-aviva-lev-ari-phd-rn-founder-of-pharmaceuticalintelligence-com-by-perplexity-ai-and-by-googles-gemini-2/

 

Updated on 3/6/2025

Today, we celebrate our Website milestone: +2.3MM views, +1.5MM visitors and +6,200 Scientific articles

[Views: 2,360,125, Visitors: 1,500,187, Scientific articles: 6,226]

attn: PostDocs in Life Sciences – we need you

attn: Computer Scientist, Data Scientists and AI geeks – we need you

>>>>> contact me by e-mail:

AvivaLev-Ari@alum.berkeley.edu

IF Artificial Intelligence & Life Sciences are in your sphere of interest

THEN

Review for your own GROWTH and education on HOT topics:

1. Advanced AI: TRAINING DATA, Sequoia Capital Podcast, 31 episodes

Reporter: Aviva Lev-Ari, PhD, RN

Advanced AI: TRAINING DATA, Sequoia Capital Podcast, 31 episodes

2. Healthcare Foundation Model

Mission: Design of an Artificial Intelligence [AI-built] Healthcare Foundation Model driven by and derived from Medical Expert Content used as Training Data

Multimodal Healthcare Foundation Model

3. AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare

We cover here advances in Machine Learning and Large or Small Language Models in Healthcare, Pharmaceutical, Medical and Life Sciences

AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare

Updated on 3/5/2025

  • Advanced AI: TRAINING DATA, Sequoia Capital Podcast, 31 episodes

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2025/02/27/advanced-ai-training-data-sequoia-capital-podcast-31-episodes/

  • Healthcare Foundation Model

Mission: Design of an Artificial Intelligence [AI-built] Healthcare Foundation Model driven by and derived from Medical Expert Content used as Training Data

https://pharmaceuticalintelligence.com/healthcare-foundation-model/

  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare

We cover here advances in Machine Learning and Large or Small Language Models in Healthcare, Pharmaceutical, Medical and Life Sciences

https://pharmaceuticalintelligence.com/deepseek-expert-models-in-healthcare/

 

Updated on 2/18/2025

See Updated for

AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare

Updated on 2/1/2025

Today we launched 

Grok, DeepSeek & Expert Models in Healthcare

https://pharmaceuticalintelligence.com/deepseek-expert-models-in-healthcare/

 

Updated on 1/22/2025

Paul G. Yock, Recipient of the 2024 National Medal of Technology and Innovation, Professor of Cardiovascular Medicine at Stanford Medical School

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2025/01/16/paul-g-yock-recipients-of-the-2024-national-medal-of-technology-and-innovation-professor-of-cardiovascular-medicine-at-stanford-medical-school/

 

Recipients of the 2024 National Medal of Technology and Innovation, administered by President Joe Biden and Laureates of the National Medal of Science, administered by NSF

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2025/01/13/recipients-of-the-2024-national-medal-of-technology-and-innovation-administered-by-president-joe-biden-and-laureates-of-the-national-medal-of-science-administered-by-nsf/

 

@@@

UPDATED on 1/15/2025 Due to personal reasons Dedeep Surampudi withdrew his intended start of a CS Internship with LPBI Group. On 1/15/2025 his CV was removed from our records.

2024

UPDATED on 12/3/2024

On 12/2/2024 we added to our IT Team:

Dedeep Surampudi, Research Assistant 3, Data Scientist and Core Applications Developer

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/dedeep-surampudi-research-assistant-3-data-scientist-and-core-applications-developer/

Dedeep Surampudi, PERSONAL PAGE, Research Assistant 3, Data Scientist and Core Applications Developer

https://pharmaceuticalintelligence.com/sop-web-stat/dedeep-surampudi-personal-page-research-assistant-3-data-scientist-and-core-applications-developer/

Dedeep’s roles at LPBI Group are:

Task #1: Extract Article Views for each year: 2020-2024 and cumulative totals for 1/1/2020 to 1/1/2025

Task #2: Extract Updates for Top Authors Web Stat and Top 14 articles

Task #3: Write code in X.com language to update all followers of two handles > 500 since 1/2016 to Present

Task #4: Update Equity sharing data using updates from Task 2, above

Task #5: Under mentorship build a Foundation Model for Galectines using LLM and GPT 4.0

 

 

UPDATED on 10/19/2024

Nobel Prize in Physics 2024 to J.J. Hopfield and to G.E. Hinton 

https://pharmaceuticalintelligence.com/2024/10/08/nobel-prize-in-physics-2024-j-j-hopfield-and-to-g-e-hinton/

Nobel Prize in Chemistry 2024 to David Baker, Demis Hassabis and John M. Jumper

https://pharmaceuticalintelligence.com/2024/10/09/nobel-prize-in-chemistry-2024-to-david-baker-demis-hassabis-and-john-m-jumper/

2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation

https://pharmaceuticalintelligence.com/2024/10/08/2024-nobel-prize-in-physiology-or-medicine-jointly-to-victor-ambros-and-gary-ruvkun-for-the-discovery-of-microrna-and-its-role-in-post-transcriptional-gene-regulation/

 

UPDATED on 10/8/2024

Tweet Collection for MIT EmTech, September 30, 2024 – October 1, 2024 on MIT Campus, Cambridge, MA Big Ideas, Big Decisions, Big Impact.

https://pharmaceuticalintelligence.com/2024/10/08/tweet-collection-for-mit-emtech-september-30-2024-october-1-2024-on-mit-campus-cambridge-ma-big-ideas-big-decisions-big-impact/

 

Tweet Collection for 10th annual World Medical Innovation Forum (WMIF) Monday, Sept. 23–Wednesday, Sept. 25 at the Encore Boston Harbor in Boston

https://pharmaceuticalintelligence.com/2024/10/08/tweet-collection-for-10th-annual-world-medical-innovation-forum-wmif-monday-sept-23-wednesday-sept-25-at-the-encore-boston-harbor-in-boston/

 

UPDATED on 9/20/2024

In the AI and Cardiovascular field, we posted three new articles

DASI Simulations, OH-based company gained FDA clearance for an artificial intelligence (AI) Product that identifies and measures cardiac structures in CT scans

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2024/09/20/dasi-simulations-oh-based-company-gained-fda-clearance-for-an-artificial-intelligence-ai-product-that-identifies-and-measures-cardiac-structures-in-ct-scans/

 

Israeli vendor AISAP gained FDA clearance for its new AI-enabled, point-of-care ultrasound (POCUS) software platform, AISAP Cardio

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2024/09/20/israeli-vendor-aisap-gained-fda-clearance-for-its-new-ai-enabled-point-of-care-ultrasound-pocus-software-platform-aisap-cardio/

 

JACC editor ‘very important moment’ for Cardiology: New drugs for obesity and prevention, New tools for structural heart analysis for Heart Failure, AI harnessed for Cardiac patient monitoring

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2024/09/20/jacc-editor-very-important-moment-for-cardiology-new-drugs-for-obesity-and-prevention-new-tools-for-structural-heart-analysis-methods-for-heart-failure-ai-harnessed-for-cardiac-monitoring/

 

UPDATED on 9/16/2024

VIRTUAL CONFERENCES covered by

Aviva Lev-Ari, PhD, RN

2024

10th annual World Medical Innovation Forum (WMIF) Monday, Sept. 23–Wednesday, Sept. 25 at the Encore Boston Harbor in Boston

https://pharmaceuticalintelligence.com/2024/09/10/10th-annual-world-medical-innovation-forum-wmif-monday-sept-23-wednesday-sept-25-at-the-encore-boston-harbor-in-boston/

MIT EmTech, Monday, September 30, 2024 – Tuesday, October 1, 2024 on MIT Campus, Cambridge, MA. Big Ideas. Big Decisions. Big Impact. In-person and online

https://event.technologyreview.com/emtech-mit-2024/home?uid=66dfa06b511c5

https://pharmaceuticalintelligence.com/2024/09/16/mit-emtech-monday-september-30-2024-tuesday-october-1-2024-on-mit-campus-cambridge-ma-big-ideas-big-decisions-big-impact-in-person-and-online/

VIRTUAL CONFERENCES covered by

Stephen J. Williams, PhD

2024

Live Notes from JP Morgan Healthcare Conference Virtual Endpoints Preview: January 8-9 2024

https://pharmaceuticalintelligence.com/2024/01/16/live-notes-from-jp-morgan-healthcare-conference-virtual-endpoints-preview-january-8-9-2024/

 

UPDATED ON 8/25/2024

Effective 8/22/2024 Change of Name and Incorporation to LLC

 

Leaders in Pharmaceutical Business Intelligence Group, LLC

Doing Business As:

LPBI Group, Newton, MA

Web Site

https://pharmaceuticalintelligence.com/

 

The General Purpose of the LLC is:

“To establish, conduct, and carry on the business of accumulating and developing healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries and related technological approaches, i.e., curation and text analysis with machine learning and any other activity which is related to such pursuits and to enable it to pursue any business and authority conferred by the Commonwealth of Massachusetts upon limited liability companies created under M.G.L. Chapter 156C.”

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence Group, LLC

DBA

LPBI Group, Newton, MA 

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

         LinkedIn Profile        Twitter Profile

 

Updated on 5/7/2024

All our Books are Expert Insights eBooks on PHARMACEUTICS

We are so proud of this accomplishment by LPBI Group !!!!!!

  • The one publisher with +147,000 page downloads

SEE our 37 books on Amazon.com – Kindle Store 

[17 books with 18 volumes in English, 19 books with 19 volumes in Spanish] N = 36 books, 37 volumes

[5 bundles in English by e-Series] 

[5 bundles in Spanish by e-Series]

Total: 37 + 10 = 47 + Library of Audio Podcasts volume = 48

= 48 volumes in 47 books

[English Edition, Series D: Immunology – Volume 2 & 3 were published in one book]

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss

and

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&qid=1715011948&ref=sr_pg_1

  • SEE our Five BUNDLES – Five e-Series in English Edition on Amazon.com – Kindle Store

URLs for the English-Language Edition by e-Series:

Series A: Cardiovascular Diseases ($515)

https://www.amazon.com/gp/product/B07P981RCS?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

Series B: Frontiers in Genomics ($200)

https://www.amazon.com/gp/product/B0BSDPG2RX?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks

Series C: Cancer & Oncology ($175)

https://www.amazon.com/gp/product/B0BSDWVB3H?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

Series D: Immunology ($325)

https://www.amazon.com/gp/product/B08VVWTNR4?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks

Series E: Patient-Centered Medicine ($274)

https://www.amazon.com/gp/product/B0BSDW2K6C?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

 

  • SEE our Five BUNDLES – Five e-Series in Spanish language Edition on Amazon.com – Kindle Store

URLs for the Spanish-language Edition by e-Series:

Serie A: Enfermedades cardiovasculares ($385)

https://www.amazon.com/gp/product/B0BPR9L1ZX?ref_=dbs_p_pwh_rwt_anx_a_lnk

Serie B: Fronteras de la investigación genómica ($305)

https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tuk

Serie C: Cáncer y la oncología ($231)

https://www.amazon.com/dp/B0BQHMRK3C?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

Serie D: Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr ($268)

https://www.amazon.com/dp/B0BR8P5TST

Serie E: Medicina centrada en el paciente ($217)

https://www.amazon.com/dp/B0BRGMCM8Q?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

 

Updated on 4/1/2024

Ownership Transfer by LPBI Group 

 

Digital Contents Ready for Digitization to 0 and 1:

  • IP Digital Asset Classes I, II, III, V, X

LPBI Group’s five IP Digital Assets Classes representing +8GB of data:

  • IP Asset Class I: Journal, 2.3MM views, 6200 articles, ~70% curations https://pharmaceuticalintelligence.com/
  • IP Asset Class II: 48 e-Books: English-language Edition, Spanish-language Edition and five e-Series bundles for each language
    • https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
  • IP Asset Class III: 100 e-Proceedings & 50 Tweet collections of experts quotes made during Biotech and Medical Conferences
  • IP Asset Class V: +8,000 biological Images
  • IP Asset Class X: +300 Audio Podcasts Library – Biological Sciences Discoveries in the 21st Century

 

Ready for Valuation of e-Reputation and e-Recognition used for quality measurement:

  • IP Digital Asset Class VI: Human Capital: The Bio of contributors for IP Digital Asset Classes I, II, III, V, X, above
  • IP Digital Asset Class IX: Intangibles assets representing unparalleled e-Reputation of the Intellectual Property created

https://pharmaceuticalintelligence.com/intangibles-cim/

  • IP Digital Asset Class VIII: +9300 subscribers to Pharmaceutical Intelligence

https://pharmaceuticalintelligence.com/

  • IP Digital Asset Class VII: Royalties transferred by Amazon.com for 145,000-page downloads
  • IP Digital Asset Class IV: Composition of Methods: Workflows, SOPs, Protocols, Portals, Editor’s Dashboard

 

Updated on 3/21/2024

 GTC March 2024 Keynote with NVIDIA CEO Jensen Huang

https://www.youtube.com/watch?v=Y2F8yisiS6E

Keynote by NVIDIA CEO Jensen Huang | GTC 2024 | NVIDIA

https://www.nvidia.com/gtc/keynote/?nvid=nv-int-unbr-914612

These CEO’s presentations on new more powerful AI computation platform represent a revolution called MicroServices for BioPharma on the Supercomputer of NVIDIA, called Blackwell.

‘An AI foundry’: Nvidia’s Jensen Huang pitches biotech on easy AI, with focus on software going beyond chips.

We at LPBI Group, believe that we need to approach 

  • Kimberly Powell, Nvidia’s vice president of healthcare
  • BioNeMo is the compute environment for Healthcare
  • discuss with her LPBI Group’s ontology, curated, annotated and structured CONTENT as a series of digital assets that READY for digitation to 1 and 0 and become part of Blackwell firmware or server resident as any other database in biological sciences, mentioned, below.

Relevant to BioNeMo are the following LPBI Group’s five IP Digital Assets Classes representing +7GB of data:

  • IP Asset Class I: Journal, 2.3MM views, 6200 articles, ~70% curations https://pharmaceuticalintelligence.com/
  • IP Asset Class II: 48 e-Books: English-language Edition, Spanish-language Edition and five e-Series bundles for each language
    • https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
  • IP Asset Class III: 100 e-Proceedings & 50 Tweet collections of experts quotes made during Biotech and Medical Conferences
  • IP Asset Class V: +8,000 biological Images
  • IP Asset Class X: +300 Audio Podcasts Library – Biological Sciences Discoveries in the 21st Century

We, at LPBI Group agree, since 11/2023, the launch of ChatGPT, GPT-4 and the forthcoming GPT-5 – all represent new opportunities for LARGE LANGUAGE MODELS (LLM) that had emerged with new capabilities of Artificial Intelligence applications for BioPharma.

In this direction, since announcements made at NVIDIA at its GTC, on 3/17 – 3/21/2024, a new platform by NVIDIA named Blackwell was presented which represents two NEW strategic dimensions on Artificial Intelligence applications for BioPharma:

  1. New hardware architecture allowing for execution of Neuro Networks (NN) computations very cheaply, thus, training a model with very large number of parameters becomes accessible and affordable 
  2. NVIDIA has announced a new business model named MicroServices. Like the concept of MicroPayments:
  • Pay per Use for services offered by a shared Cloud 
  • You bring your requirements and data to NVIDIA Cloud, enjoy an amazing platform, dashboard features, run your models and programs ON A SHARED PLATFORM provided by NVIDIA and 
  • Pay for one MictoService or for several of them in parallel

Option a: One $ per 1 hour of platform use

or

Option b: $4,700 subscription for unlimited use

  1. For Healthcare and BioPharma applications:  this is where LPBI Group’s content (curated, annotated and structured) is very pointed

NVIDIA via collaboration with 

A. Google’s: AlphaFold and DeepMind databases on Protein structures

B. MIT’s Broad Institute Genomics 🧬 gene structure sequences

C. National Institute of Cancer Research and NIH Cell Atlases

D. Other very large data bases on Genomics and Cancer

on its new Blackwell platform which is 

  1. Designed for NN computations, and 
  2. Having seamless access or embedding of A, B, C, D, above – ALL databases been residents of NVIDIA’s Cloud (?), and
  3. Allowing for MicroPayments named MicroServices, pay for how much you use the NVIDIA’s Cloud compute INTEGRATED environment: Hardware, Software, Databases

NVIDIA’s Blackwell is enabling 

  • ACCESS to the most powerful COMPUTE environment in the World and 
  • ACCESS to ALL the Genomics databases needed for BioPharma applications such as a newly potentiated ACCELERATED Drug Discovery process

We, at LPBI Group believe that 

  • NVIDIA’s Blackwell Platform which embed 

— FAST and CHEAP Hardware

— NN software, and 

— dedicated Databases in the Biological Sciences that include: 

  • Gene structure Atlases
  • Cell structure Atlases
  • Molecule structure Libraries
  • Medicinal Chemistry tables
  • FDA approved Drug Formulary 

that NVIDIA will be a MAJOR business disruption for companies like Illumina and its competitors that has genomic sequencing platform and clusters of hardware/software configurations that are MOST EXPENSIVE that you have to buy to do the job.

Blackwell platform allows for performance of genomic sequencing as a step in the computation environment led by AI driven functionality.

  • Blackwell is “soup to nuts” solution not just a sequencing platform which generate the input or one of the inputs for drug discovery and drug design must use for:
  • Gene->Disease->Drug

As you complete the use of the NVIDIA’s Cloud you take with you on your device all the data back and the results generated.

In this newly emerging Research environment geared for acceleration of the Drug Discovery and Drug Design PROCESS as described in:

Accelerate Drug Discovery With Generative AI

https://resources.nvidia.com/en-us-hc-biopharma/hc-solution-overview-5

Nvidia CEO Jensen Huang pitches easy AI, launches microservices for biotech – Endpoints News

https://endpts.com/nvidia-ceo-jensen-huang-pitches-easy-ai-launches-microservices-for-biotech/

‘An AI foundry’: Nvidia’s Jensen Huang pitches biotech on easy AI, with focus on software going beyond chips

https://endpts.com/nvidia-ceo-jensen-huang-pitches-easy-ai-launches-microservices-for-biotech/

LPBI Group’s contents need to be positioned as Clinical Experts curated content.

Statement explained:

  1. Every curation in LPBI Group’s Journal • represents a clinical interpretation by a domain knowledge expert 
  2. Every book in our 48 URLs on Amazon
  • represents a Domain Knowledge Expert DESIGN of an electronic Table of Contents, a total view of a field of inquiry in Medicine
  • represents collection of chapters that were created by Expert selection of inclusion of articles for each of the chapters

3. e-Proceedings (N=100) and Tweet collections (N=50)

4. Every Biological Image in the Media Gallery (~8,000) was 

  • selected by an Expert for inclusion into an article
  • The book editor selected this article for inclusion into a chapter
  • The book editor selected which chapters to be included in the book

Series Editors selected which books to be included in a Series that represents a Specialty in Medicine. We covered the following FIVE:

– Series A: Cardiovascular

– Series B: Genomics

– Series C: Cancer

– Series D: Immunology

– Series E: Precision Medicine

THESE are all layers of domain expertise that are ABSENT in the PubMed archive that includes of every article published by an author whose research was sponsored by government funding

  • Each article represents ONE experiment, or
  • One Clinical Trial at a time
  • Meta analysis represents several experiments or several clinical trials – they are less than 1% of all entries in PubMed. 

Every curation in our Journal involves 5-15 external sources

5. LPBI Group’s Library of Podcasts +300 on Biological Discoveries:

  • All are curations
  • Their classification into 21 chapters was performed by Experts: Prof. Feldman and Dr. Williams
  • Identification of all podcasts that involve Women or deal with Research funding alternatives was performed by Experts: Dr. Williams and Aviva

NOTE: Aviva as Editor-in-Chief of the BioMed e-Series (IP Asset Class II in the portfolio) 

  • Announced all book titles
  • Announced all e-Series titles
  • Launched the category of research that allowed the Podcast Library to be built
  •  convert all curations into Audio files
  • Library INDEX to be published in 2023.

For the NVIDIA’s Blackwell Platform

  • LPBI Group’s IP DIGITAL ASSET CLASSES of relevance are:

IP Class I. Journal articles – Text & Images

IP Class II. Books – Text & Images 

IP Class III. e-Proceedings & Tweets – Global Conference quotes in Text on Social Media

IP Class V. Biological Images Media Gallery – Images with text captions

IP Class X. Podcast Library – Text & Audio files

 

These IP Classes are FIVE dedicated DATA BASES of 

  • DIGITAL files ready for digitization into 1 and 0
  • Structured data ready for digitization into 1 and 0

 

Updated on 3/4/2024

LPBI Group announces new Talent additions in the Business Development domain:

John Lahaye, Member Business Advisory Board, Business Development CRO economic segment

https://pharmaceuticalintelligence.com/contributors-biographies/business-development-private-equity-investment/john-lahaye-member-business-advisory-board-business-development-cro-economic-segment/

 

The Voice of Aviva Lev-Ari, 2.0 LPBI, Founder

Updated on 2/1/2024

2.0 LPBI Group – Executive Summary

https://pharmaceuticalintelligence.com/2-0-lpbi-executive-summary/

 

Updated on 1/28/2023

12/24/2023 is the date of publication of the Audio Podcast Library

Contributions to Biological Sciences by Scientific Leaders in the 21st Century:

BioMed Audio Podcast Library by LPBI Group 301 Interviews & Discovery Curations 

Kindle Edition

by Dr. Larry H. Bernstein (Author), Dr. Stephen J. Williams (Author), Dr. Aviva Lev-Ari (Author)  Format: Kindle Edition

https://www.amazon.com/dp/B0CQXL5MTW

on LPBI Group Website:

https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/

@@@@@@@@@@@

2023

Updated on 6/11/2023

Health Care Policy Analysis derived from the Farewell remarks from AMA President Jack Resneck Jr., MD | AMA 2023 Annual Meeting

Curators: Aviva Lev-Ari, PhD, RN, Stephen J. Williams, PhD and Prof. Marcus W. Feldman

https://pharmaceuticalintelligence.com/2023/06/10/health-care-policy-analysis-derived-from-the-farewell-remarks-from-ama-president-jack-resneck-jr-md-ama-2023-annual-meeting/

 

Gerald “Jerry” Austen, MD influential in the design and creation of a cardiopulmonary (heart-lung) bypass machine and the intra-aortic balloon pump at MGH as renowned cardiac surgeon

Curator and reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2023/06/09/w-gerald-jerry-austen-md-influential-in-the-design-and-creation-of-a-cardiopulmonary-heart-lung-bypass-machine-and-the-intra-aortic-balloon-pump-at-mgh-as-renowned-cardiac-surgeon/

 

Updated on 6/6/2023

LPBI Group’s Mission #5:

Phase 1:

  • Will create a Pilot Prototype for all LPBI Group’s 300 Audio Podcast: Design an Autonomous Medical Text Update System with ChatGPT

Phase 2:

  • Will Scale up the Pilot for a new IT project: Autonomous Medical Text Update System for 6,170 Scientific articles in http://pharmaceuticalintelligence.com 

 

Updated on 5/5/2023

LPBI Group will cover 2023 World Medical Innovation Forum in Real Time.

From: “Doyle, Tracy” <tdoyle5@mgb.org>
Date: Friday, May 5, 2023 at 2:35 PM
Subject: Media Invite: World Medical Innovation Forum — June 12-14, Boston

To: Aviva Lev- Ari, PhD, RN

Media Invite: World Medical Innovation Forum: Monday, June 12—Wednesday, June 14, Boston

Exploring innovation and investment in Brain Health/CNS, Oncology, and Inflammation & Immunology

Mass General Brigham, one of the nation’s leading academic medical centers, is pleased to invite media to attend the annual World Medical Innovation Forum (WMIF) Monday, June 12 – Wednesday, June 14 at the Westin Seaport in Boston. The event features expert discussions of scientific and investment trends related to three areas of medicine poised for near-term breakthroughs: brain health and central nervous system disorders (CNS), oncology, and inflammation & immunology. The agenda features nearly 175 executive speakers from healthcare, pharma, venture, start-ups, and the front lines of care, including many of Mass General Brigham’s Harvard Medical School-affiliated researchers and clinicians. Bank of America, presenting sponsor of the Forum, will provide additional insights on the investment landscape associated with these areas of healthcare innovation. 

Forum highlights include:

1:1 interviews with leading CEOs and government officials including:

Robert Califf, MD, U.S. Commissioner of Food and Drugs, FDA

Sree Chaguturu, MD, CMO, CVS

Mikael Dolsten, MD, PhD, CSO, Pfizer

Anne Klibanski, MD, President and CEO, Mass General Brigham

Brian Moynihan, CEO, Bank of America

David Ricks, CEO, Eli Lilly and Company

Chris Viebacher, CEO, Biogen

Renee Wegryzn, PhD, Director, ARPA-H

Plenary Sessions – expert panels including:

  • The Next Wave of Promising Psychiatry and Neurology Drugs
  • The Science of Happiness
  • The Innovation Gap: Emerging Modalities and Mechanisms for Treating CNS Disease
  • The Biologic Revolution in Cancer
  • Driving Cell Therapy into Solid Tumors
  • Precision Oncology for Liquid Tumors
  • Reprogramming the Immune System
  • Emerging Targets in Inflammation & Immunology
  • Capital Formation in Healthcare – Trends and Opportunities

Leading biotech speakers from companies including:

  • Amylyx
  • BioXcel
  • Cognition Therapeutics
  • QurAlis
  • Mammoth Biosciences
  • Compass Therapeutics
  • Immunopharma
  • Boundless Bio
  • Intellia
  • AlloVir

Exclusive programming:  

  • First Look – 16 rapid-fire presentations from leading Mass General Brigham researchers in brain health/CNS, oncology, inflammation & immunology
  • The Doctor is In – A series of concurrent learning sessions presented by senior Mass General Brigham clinicians and Bank of America analysts, including a session on the impact of Boston-based biotech innovation incubators and accelerators
  • Disruptive Dozen – Announcement of 12 break-through technologies likely to emerge in clinical use in the next few years

WMIF full agenda and list of speakers 

Register Now:

For complimentary media registration, click the link below.

Tracy

Follow us on Twitter @MGBInnovation

Tracy M. Doyle

Marketing & Communications Director, Innovation

Mass General Brigham

399 Revolution Drive, Suite 955, Somerville, MA 02145

T 262-227-5514

tdoyle5@partners.org
innovation.partners.org

 

Updated on 2/14/2023

Press Release for Five Bilingual BioMed e-Series in English and in Spanish

https://pharmaceuticalintelligence.com/2023/01/29/press-release-for-five-bilingual-biomed-e-series/

 

Updated on 2/14/2023

2023 Update from LPBI Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

 

Updated on 2/12/2023

UPDATED to 1/1/2023 –>> February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical & Life Sciences Research Categories, 10,440 Tags, Top Article 17,300 Views, Top Author 487,500 Views on PharmaceuticalIntelligence.com

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

 

Updated on 1/19/2023

Five Bilingual BioMed e-Series – 37 volumes

Curator, Book Editor & Bilingual BioMed e-Series, Editor-in-Chief:

Aviva Lev-Ari, PhD, RN

  • English Edition:  18 volumes in 17 books, and
  • Spanish Edition (EDICIÓN EN ESPAÑOL): 19 volumes in 19 books

https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/

Updated on 12/31/2022

We are VERY proud to have been successful in publishing our

Spanish Edition: Series A, B, C, D in 2022

Series E in the 1st week in 1/2023 

LPBI GROUP IS PUBLISHER  

on Kindle Edition of

37 e-Books in Medicine and Life Sciences

  • All by our Team members
  • All books with one Editor-in-Chief
  • All contents “Invented here”

 

Serie A

Serie A: libros electrónicos acerca de las enfermedades cardiovasculares 

(6 books) Kindle Edition

For the Series in Spanish Audio ($385) go to

https://www.amazon.com/gp/product/B0BPR9L1ZX?ref_=dbs_p_pwh_rwt_anx_a_lnk

Spanish Series B

Fronteras de la investigación genómica

(3 book series) Kindle Edition 

For the Series in Spanish Audio ($305) go to

https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

Volume 3: Text Analysis Results of NLP [Madison Davis]

 

Spanish Series C

Serie C: libros electrónicos acerca del cáncer y la oncología

(2 book series) Kindle Edition

For the Series in Spanish Audio ($231) go to

https://www.amazon.com/dp/B0BQHMRK3C?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

Cancer Volume 1: Text Analysis Results of NLP [Madison Davis] – PART B

Serie D:

Libros electrónicos de Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr 

(4 book series) Kindle Edition

For the Series in Spanish Audio ($268) go to

https://www.amazon.com/dp/B0BR8P5TST

 

Spanish Series E 

Serie E: Medicina centrada en el paciente

(4 book series) Kindle Edition 

For the Series in Spanish Audio ($217) go to

https://www.amazon.com/dp/B0BRGMCM8Q?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

ADD Series Image

UPDATED on 12/30/2022

 New Genre Series B

For citation: of LPBI Group’s Genomics Volume 3 in New Genre Edition

 

Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS

https://www.amazon.com/dp/B0BRD8JXTL

Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, … de la investigación genómica Book 3) Kindle Edition

by Madison Davis (Author), Aviva Lev-Ari (Editor), Stephen J. Williams (Editor), Marcus W. Feldman (Editor)  Format: Kindle Edition

Serie B: Fronteras de la investigación genómica 

(3 book series) Kindle Edition

by Larry H. Bernstein (Author) , Stephen J. Williams (Author) , Sudipta Saha (Author) , Ritu Saxena (Author) , Tilda Barliya (Author) , Anamika Sarkar (Author) , Marcus W. Feldman (Author) , Demet Sag (Author) , Prabodh kandala (Author) , Larry H. Bernstein (Author) , Aviva Lev-Ari (Author) , Madison Davis (Author)

https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

 

UPDATED on 12/28/2022

View on Amazon.com

Serie D:

Libros electrónicos de Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr 

(4 book series) Kindle Edition

Series URL

https://www.amazon.com/dp/B0BR8P5TST

 

Volume Titles & URL on Amazon.com

Volumen 1

Genómica metabólica y farmacéutica (Serie D: Libros electrónicos de Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr nº 1)

(Spanish Edition) Kindle Edition

http://www.amazon.com/dp/B0BR8DPPZW

 

Volumen 2

Enfermedades infecciosas y terapéutica (Serie D: Libros electrónicos de Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr nº 2) (Spanish Edition)

(Spanish Edition) Kindle Edition

http://www.amazon.com/dp/B0BR8HPNK2

 

Volumen 3

El sistema inmunitario y la terapéutica (Serie D: Libros electrónicos de Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr nº 3) (Spanish Edition)

(Spanish Edition) Kindle Edition

http://www.amazon.com/dp/B0BR8GYBG7

 

Volumen 4

Sistema reproductor humano, endocrinología genómica y tipos de cáncer

(Spanish Edition) Kindle Edition

http://www.amazon.com/dp/xxxxxx

 

Volume’s Date of Publication, Price, Audio

Spanish Series D

 

 Date of Publication Spanish Edition Price English Edition

 

Price

Audio

Volumen 1

 12/28/2022 56 75

no

Volumen 2

 12/28/2022 56 2&3

 

115

yes

Volumen

3

 12/28/2022 56  

no

Volumen 4

 12/xx/2022 100 135

no

 

UPDATED on 12/21/2022

Series C, Volume 1 and Volume 2 available on Amazon.com

Serie C: libros electrónicos acerca del cáncer y la oncología(2 book series) Kindle Edition

 

  • Original Volume One: Cancer Biology and Genomics for Disease Diagnosis

On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

 

  • NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

This volume has the following three parts that are presented in the following order: A, C, B

Audio & Text

  • PART A: A1 and A2
  • PART C, followed by
  • PART B – Graphics & Text, followed by
  • Appendix to PART B – Computer Code

Format detailed

>>>> PART A: Audio & Text

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

>>>> PART C: The Editorials of the original e-Book in English in Audio format

>>>> PART B: Computer Graphics and English Text

The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

>>>> Appendix to PART B – Computer Code

Biología y genómica del cáncer para el diagnóstico de la enfermedad (Serie C: libros electrónicos acerca del cáncer y la oncología nº 1) (Spanish Edition) Kindle Edition

Spanish Edition  by Stephen J. Williams (Author), Larry H. Bernstein (Author), Dror Nir (Author), Tilda Barliya (Author), Ritu Saxena (Author), Demet Sag (Author), Aviva Lev-Ari (Author), Sudipta Saha (Author), Ziv Raviv (Author), Prabodh Kandala (Author)  Format: Kindle Edition

View on Amazon.com

https://www.amazon.com/dp/B0BQHFXKHH

 

  • Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

On Amazon.com since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

 

  • NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-two-cancer-therapies-metabolic-genomics-interventional-immunotherapy-and-nanotechnology-in-therapy-delivery-series-b-volume-2%ef%bf%bc/

Tratamientos contra el cáncer: Metabólicos, genómicos, intervencionistas, inmunoterapia y nanotecnología para la administración de tratamientos

(Spanish Edition) Kindle Edition

Spanish Edition  by Larry H. Bernstein (Author), Stephen J. Williams (Author), Tilda Barliya (Author), Aviva Lev-Ari (Author), Demet Sag (Author), Dror Nir (Author), Ziv Raviv (Author), Evelina Cohn (Author), Danut Dragoi (Author)  Format: Kindle Edition

View on Amazon.com

https://www.amazon.com/dp/B0BQTM44SM

 

UPDATED on 12/19/2022

Citation STARTS:

 

Biología y genómica del cancer para el diagnóstico de la enfermedad (Spanish)

Spanish Edition on Amazon.com

https://www.amazon.com/dp/B0BQHFXKHH

 

Cancer Biology and Genomics for Disease Diagnosis 

(English)

On com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

In Spanish Edition,

This volume include graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format.

PART B: NLP by Madison Davis, Data preparation by Danielle Smolyar and Premalata Pati, PhD with Interpretation of NLP results by Stephan J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

Citation ENDS

 

UPDATED on 12/18/2022

Serie B: Fronteras de la investigación genómica

 

PRIMER VOLUMEN

EDICIÓN EN ESPAÑOL

 

Traducción en español

Montero Language Services

 

Orientaciones genómicas para la medicina personalizada

View on Amazon.com

https://www.amazon.com/dp/B0BQGZRQ2C

 

and

 

Serie B: Fronteras de la investigación genómica

 

SEGUNDO VOLUMEN

EDICIÓN EN ESPAÑOL

 

Traducción a español

Montero Language Services

 

Lo último en metodologías genómicas para agentes terapéuticos: edición génica, SMP y bioinformática, simulaciones y la ontología del genoma

View on Amazon.com

https://www.amazon.com/dp/B0BQH14CSF

 

UPDATED on 12/13/2022

The original 6 volumes in Series A: Cardiovascular Diseases in

English Text Edition are found on Amazon.com

For the Series in English text ($515) go to

https://www.amazon.com/dp/B07MVF34ZC/ref=sr_1_1?s=digital-text

or
https://lnkd.in/e6WkMgF

 

12/12/2022 News starts here

 

The original 6 volumes in Series A: Cardiovascular Diseases in

Spanish Translation Edition are found on Amazon.com
 

For the Series in Spanish Audio ($385) go to

https://www.amazon.com/gp/product/B0BPR9L1ZX?ref_=dbs_p_pwh_rwt_anx_a_lnk

 

UPDATED on 12/12/2022

Aviva on Kindle Direct Publishing of 

Audio English-Spanish: BioMed e-Series

EDICIÓN EN ESPAÑOL

Indice de contenidos electrónico (IDCe)

AUDIO y TEXTO

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

Spanish Edition, Series A: WE ARE on AMAZON.com

Series A, Volume 1:

Puntos de vista acerca del óxido nítrico en los mecanismos patogénicos

 https://www.amazon.com/dp/B0BPST4B4N

Series A, Volume 2:

Investigación original cardiovascular: casos de diseño de metodología para la selección de contenidos El arte de la selección de contenidos científicos y médicos

 https://www.amazon.com/dp/B0BPRBVLD3

Series A, Volume 3:

Etiología de las enfermedades cardiovasculares: epigenética, genética y genómica

 https://www.amazon.com/dp/B0BPR8ZCT3

Series A, Volume 4:

Medicina regenerativa y Medicina traslativa La promesa terapéutica para las enfermedades cardiovasculares

 https://www.amazon.com/dp/B0BPRC2WQY

Series A, Volume 5:

Agentes farmacológicos en el tratamiento de las enfermedades cardiovasculares

 https://www.amazon.com/dp/B0BPRCZ1QF

Series A, Volume 6:

Cardiología intervencionista para el diagnóstico de enfermedades y cirugía cardíaca para el tratamiento de afecciones

 https://www.amazon.com/dp/B0BPRDLFNH

Series A, Volume 1: https://www.amazon.com/dp/B0BPST4B4N

Series A, Volume 2: https://www.amazon.com/dp/B0BPRBVLD3

Series A, Volume 3: https://www.amazon.com/dp/B0BPR8ZCT3

Series A, Volume 4: https://www.amazon.com/dp/B0BPRC2WQY

Series A, Volume 5: https://www.amazon.com/dp/B0BPRCZ1QF

Series A, Volume 6: https://www.amazon.com/dp/B0BPRDLFNH

 

UPDATED ON 10/20/2022

The factors effecting the IP Valuation of LPBI Group are described in:

  • Portfolio of IP Assets

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

 

  • 2.0 LPBI is a Very Unique Organization – Section Valuation & Stream of Innovations

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

 

  • 2022 Update from LPBI Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

 

  • 2.0 LPBI, Strategy #2: Blockchain Transactions Network Ecosystem

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

 

  • NFT: Redefined Format of IP Assets

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

 

  • Audio English-Spanish: BioMed e-Series          

EDICIÓN EN ESPAÑOL

Indice de contenidos electrónico (IDCe)

AUDIO y TEXTO

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

 

UPDATED on 8/30/2022

LPBI Group’s elevator Pitch

https://pharmaceuticalintelligence.com/2020/10/20/versions-of-lpbi-groups-elevator-pitch-2-0-lpbi-groups-team-in-our-own-words/ 

LPBI Group’s ventures need to be positioning us as two ventures:

  • 1.0 LPBI, 2012 – 2020 – a scientific publisher
  • 2.0 LPBI Group, 2021 – 2025 – a software powerhouse with four missions (pipelines)

2022-2023 Elevator Pitch needs to incorporate the following achieved Milestones/accomplishments to date

This Elevator Pitch for 1.0 LPBI, 2012 – 2020 does not include all the PROGRESS accomplished at 2.0 LPBI Group, 2021 – 2025:

https://pharmaceuticalintelligence.com/2020/10/20/versions-of-lpbi-groups-elevator-pitch-2-0-lpbi-groups-team-in-our-own-words/

 

Status of 2.0 LPBI Group’s four pipelines is as follows:

 

Mission #1: NLP (completed): 

NEW GENRE NLP

  • Genomics Volume Three and 
  • NEW GENRE Cancer Volume One 

both include the Text analysis of the respective original volume processed by NLP algorithms: What are the results and the Domain Knowledge Expert interpretation

 

  • 2.0 LPBI Group’s Mission #1 (Text analysis with AI) 

Series B: Genomics

New volume 

NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP).  It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

 

Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish

  • Original Volume One: Cancer Biology and Genomics for Disease Diagnosis

On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART A:

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B:

The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

PART C:

The Editorials of the original e-Book in English in Audio format

 

Mission #2: Blockchain & NFT – work-in-progress

  • Erich is the Lead 
  • Results of DB Schema Phase 1 will be presented on 9/13 in the Board meeting

Please review

Blockchain Infrastructure we are developing for content monetization [2.0 LPBI Group’s Mission #2]

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

and 

NFT minting of our IP [2.0 LPBI Group’s Mission #2]

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

 

Mission #3: Completion of the Spanish translation of eTOCs for all our 18 BioMed e-Series 

  • Mission #3 (Spanish Translation and RE-publishing 18 books as NEW GENRE BioMed e-Series: 

Audio English-Spanish: BioMed e-Series

EDICIÓN EN ESPAÑOL

Indice de contenidos electrónico (IDCe)

AUDIO y TEXTO

Please review

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

Mission #4: Galectins – Drug discovery with software [2.0 LPBI Group’s Mission #4]

– work-in-progress 

  • Dr. Williams is the Lead  

Please review

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

 

UPDATED on 8/5/2022

The Multimedia new format creates a 

NEW GENRE OF SCIENTIFIC BOOK

Each NEW book has three parts:

PART A: The eTOCs in Spanish in Audio format [Spanish Text-To-Spanish Sound]

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format [English Text-To-English Sound]

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

Date of SOUND upload to Amazon, tba

SEE ALL TEXTS in the links, below

 

Scientific Books e-Series

New Genre: Audio English-Spanish

Spanish Translation performed by

Montero Language Service, Madrid, Spain 

 

  • NEW GENRE Audio English-Spanish – Series A: e-Books on Cardiovascular Diseases

 

Series A: Six volumes – e-Books on Cardiovascular Diseases NEW GENRE Audio English-Spanish

http://www.amazon.com/dp/B00DINFFYC

Original book on com since 6/21/2013

  • NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms – Series A: Volume 1

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-one-perspectives-on-nitric-oxide-in-disease-mechanisms-series-a-volume-1/

 

http://www.amazon.com/dp/B018Q5MCN8

Original Book on Amazon.com since 11/30/2015

  • NEW GENRE Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: Series A, Volume 2

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-two-cardiovascular-original-research-cases-in-methodology-design-for-content-co-curation-series-a-volume-2/

 

http://www.amazon.com/dp/B018PNHJ84

Original book on Amazon.com since 11/29/2015

  • NEW GENRE Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics – Series A, Volume 3

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-three-etiologies-of-cardiovascular-diseases-epigenetics-genetics-and-genomics-series-a-volume-3/

 

http://www.amazon.com/dp/B019UM909A

Original book on Amazon.com since 12/26/2015

  • NEW GENRE Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine – Series A, Volume 4

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-four-therapeutic-promise-cardiovascular-diseases-regenerative-translational-medicine-series-a-volume-4/

 

https://www.amazon.com/dp/B07MGSFDWR

Original book on Amazon.com since 12/23/2018

  • NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/

 

https://www.amazon.com/dp/B07MKHDBHF

Original book on Amazon.com since 12/24/2018

  • NEW GENRE Volume Six: Interventional Cardiology for Disease Diagnosis and and Cardiac Surgery for Condition Treatment – Series A, Volume 6

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-six-interventional-cardiology-for-disease-diagnosis-and-and-cardiac-surgery-for-condition-treatment-series-a-volume-6/

 

 

  • NEW GENRE Audio English-Spanish – Series B: Frontiers in Genomics Research

 

Series B: Frontiers in Genomics Research NEW GENRE Audio English-Spanish

http://www.amazon.com/dp/B018DHBUO6

On Amazon.com since 11/23/2015

  • Original Volume One: Genomics Orientations for Personalized Medicine
  • NEW GENRE Volume One: Genomics Orientations for Personalized Medicine 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/new-genre-volume-one-genomics-orientations-for-personalized-medicine-series-b-volume-1/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

 

https://www.amazon.com/dp/B08385KF87

On Amazon.com since 12/28/2019

  • Original Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology
  • New Genre Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/new-genre-volume-two-latest-in-genomics-methodologies-for-therapeutics-gene-editing-ngs-and-bioinformatics-simulations-and-the-genome-ontology-series-b-volume-2/

PART A:

A.1: The eTOCs in Spanish in Audio format AND

A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B: The graphical results of Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format – IS ISSUED AS A STANDALONE VOLUME: Volume Three  NEW GENRE Volume Three in Series B.

PART C: The Editorials of the original e-Books in English in Audio format

  • Volume Three did not exist in the Original BioMed e-Series, Series B: Frontiers in Genomics Research
  • During production it was known as PART B of Genomics, Volume Two to be published in the NEW GENRE e-Series B. It was thought to be included in Volume Two. Due to number of plots involved, a standalone volume for NLP Results and Interpretation was born, aka, Volume Three.

 

  • NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP).  It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

 

  • NEW GENRE Audio English-Spanish – Series C: e-Books on Cancer & Oncology

 

Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish

http://www.amazon.com/dp/B013RVYR2K

On Amazon.com since 12/28/2019

  • Original Volume One: Cancer Biology and Genomics for Disease Diagnosis
  • NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART A:

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B:

The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

PART C:

The Editorials of the original e-Book in English in Audio format

 

http://www.amazon.com/dp/B071VQ6YYK

On Amazon.com since 5/18/2017

  • Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
  • NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery 

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-two-cancer-therapies-metabolic-genomics-interventional-immunotherapy-and-nanotechnology-in-therapy-delivery-series-b-volume-2%ef%bf%bc/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Book in English in Audio format

 

  • NEW GENRE Audio English-Spanish – Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology

 

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology – NEW GENRE Audio English-Spanish – Volumes 1,2,3,4.

http://www.amazon.com/dp/B012BB0ZF0

On Amazon.com since 7/21/2015

  • Original Volume One: Metabolic Genomics & Pharmaceutics
  • NEW GENRE Volume One: Metabolic Genomics & Pharmaceutics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-one-metabolic-genomics-pharmaceutics-series-d-volume-1%ef%bf%bc/

 

https://www.amazon.com/dp/B075CXHY1B

On Amazon.com since September 4, 2017

  • Original Volume Two in the Volume Two and Three combined format: Infectious Diseases and Therapeutics
  • NEW GENRE Volume Two: Infectious Diseases and Therapeutics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-two-infectious-diseases-and-therapeutics-series-d-volume-2-%ef%bf%bc/

 

https://www.amazon.com/dp/B075CXHY1B

On Amazon.com since September 4, 2017

  • Original Volume Three in the Volume Two and Three combined format: The Immune System and Therapeutics
  • NEW GENRE Volume Three:  The Immune System and Therapeutics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-three-the-immune-system-and-therapeutics-pharmaceutics-series-d-volume-3-%ef%bf%bc/

 

http://www.amazon.com/dp/B08VTFWVKM

On Amazon.com  since February 2, 2021

  • Original Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types
  • NEW GENRE Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-four-human-reproductive-system-genomic-endocrinology-and-cancer-types-pharmaceutics-series-d-volume-4-%ef%bf%bc/

 

 

  • NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine  

 

Series E: Patient-Centered Medicine & Precision Medicine – NEW GENRE Audio English-Spanish

 

https://www.amazon.com/dp/B076HGB6MZ

On Amazon.com since 10/16/2017

  • Original Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
  • NEW GENRE Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-one-the-voices-of-patients-hospitals-ceos-health-care-providers-caregivers-and-families-personal-experience-with-critical-care-and-invasive-medical-procedures-series-e-vo/

 

https://www.amazon.com/dp/B078313281

On Amazon.com since12/9/2017

  • Original Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
  • NEW GENRE Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-two-medical-scientific-discoveries-for-the-21st-century-interviews-with-scientific-leaders-series-e-volume-2%ef%bf%bc/

 

http://www.amazon.com/dp/B019VH97LU

On Amazon.com since 12/27/2015

  • Original Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
  • NEW GENRE Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-three-milestones-in-physiology-discoveries-in-medicine-and-genomics-series-e-volume-3%ef%bf%bc/

 

https://www.amazon.com/dp/B078QVDV2W

On Amazon.com since 12/30/2017

  • Original Volume Four: Medical 3D BioPrinting – The Revolution in Medicine
  • NEW GENRE Volume Four: Medical 3D BioPrinting – The Revolution in Medicine

#Spanish #Audio @pharma_BI @AVIVA1950

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-four-medical-3d-bioprinting-the-revolution-in-medicine-series-e-volume-4%ef%bf%bc/

 

HAPPY TO SHARE WITH YOU THIS MILESTONE

 

 

UPDATED on 7/22/2022

NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine  

Series E: Patient-Centered Medicine & Precision Medicine – NEW GENRE Audio English-Spanish

>>>>>> 

  • Original Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

On Amazon.com since 10/16/2017

https://www.amazon.com/dp/B076HGB6MZ

  • NEW GENRE Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-one-the-voices-of-patients-hospitals-ceos-health-care-providers-caregivers-and-families-personal-experience-with-critical-care-and-invasive-medical-procedures-series-e-vo/

This volume has the following parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>>>> 

  • Original Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders

On Amazon.com since12/9/2017

https://www.amazon.com/dp/B078313281

  • NEW GENRE Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-two-medical-scientific-discoveries-for-the-21st-century-interviews-with-scientific-leaders-series-e-volume-2%ef%bf%bc/

This volume has the following three parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>>>> 

  • Original Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics

On Amazon.com since 12/27/2015

http://www.amazon.com/dp/B019VH97LU

  • NEW GENRE Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-three-milestones-in-physiology-discoveries-in-medicine-and-genomics-series-e-volume-3%ef%bf%bc/

This volume has the following three parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>>>> 

  • Original Volume Four: Medical 3D BioPrinting – The Revolution in Medicine

On Amazon.com since 12/30/2017

https://www.amazon.com/dp/B078QVDV2W

  • NEW GENRE Volume Four: Medical 3D BioPrinting – The Revolution in Medicine 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-e-patient-centered-medicine-precision-medicine/new-genre-volume-four-medical-3d-bioprinting-the-revolution-in-medicine-series-e-volume-4%ef%bf%bc/

This volume has the following three parts:

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

 

UPDATED on 7/7/2022

Explanation on Results of Medical Text Analysis with Natural Language Processing (NLP) presented in LPBI Group’s NEW GENRE Edition: NLP on Genomics content, standalone volume in Series B and NLP on Cancer content as Part B New Genre Volume 1 in Series C

https://pharmaceuticalintelligence.com/2022/07/07/results-of-medical-text-analysis-with-natural-language-processing-nlp-presented-in-lpbi-groups-new-genre-edition-nlp-on-genomics-content-standalone-volume-in-series-b-and-nlp-on-cancer-co/

 

WORKFLOW for a Eight-Steps Medical Text Analysis Operation using NLP on LPBI Medical and Life Sciences Content

https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/

 

UPDATED on 7/6/2022

NEW GENRE Audio English-Spanish – Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology – Volumes 1,2,3,4.

 

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology – NEW GENRE Audio English-Spanish – Volumes 1,2,3,4.

>>>

  • Original Volume One: Metabolic Genomics & Pharmaceutics

  • NEW GENRE Volume One: Metabolic Genomics & Pharmaceutics

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-one-metabolic-genomics-pharmaceutics-series-d-volume-1%ef%bf%bc/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>

  • Original Volume Two & Three were published as ONE volume: 

The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications

  • In the NEW GENRE E-SERIES these two volumes are published as two standalone books

>>>

  • Original Volume Two in the Volume Two and Three combined format: Infectious Diseases and Therapeutics

  • NEW GENRE Volume Two: Infectious Diseases and Therapeutics

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-two-infectious-diseases-and-therapeutics-series-d-volume-2-%ef%bf%bc/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>

  • Original Volume Three in the Volume Two and Three combined format: The Immune System and Therapeutics

  • NEW GENRE Volume Three:  The Immune System and Therapeutics

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-three-the-immune-system-and-therapeutics-pharmaceutics-series-d-volume-3-%ef%bf%bc/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

>>>

  • Original Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types

  • NEW GENRE Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-d-e-books-on-biomedicine-metabolomics-immunology-infectious-diseases-reproductive-genomic-endocrinology/new-genre-volume-four-human-reproductive-system-genomic-endocrinology-and-cancer-types-pharmaceutics-series-d-volume-4-%ef%bf%bc/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

 

UPDATED on 7/2/2022

NEW GENRE Audio English-Spanish – Series C: e-Books on Cancer & Oncology

 

Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish

  • Original Volume One: Cancer Biology and Genomics for Disease Diagnosis

  • NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART A:

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B: The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

PART C: The Editorials of the original e-Book in English in Audio format

Subpage:

Cancer, Volume 1: NLP results – 12 Hypergraph Plots and 12 Tree diagram Plots by Madison Davis

https://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-volume-1-nlp-results-12-hypergraph-plots-and-12-tree-diagram-plots-by-madison-davis/

 

  • Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

  • NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-two-cancer-therapies-metabolic-genomics-interventional-immunotherapy-and-nanotechnology-in-therapy-delivery-series-b-volume-2%ef%bf%bc/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Book in English in Audio format

 

UPDATED on 6/28/2022

Cancer, Volume 1: NLP results – 12 Hypergraph Plots and 12 Tree diagram Plots by Madison Davis

https://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-volume-1-nlp-results-12-hypergraph-plots-and-12-tree-diagram-plots-by-madison-davis/

This is a Subpage to 

  • NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART B: The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

@@@@

  • Genomics, Volume 2: NLP results – 38 or 39 Hypergraph Plots and 38 or 39 Tree diagram Plots by Madison Davis

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/genomics-volume-2-nlp-results-38-or-39-hypergraph-plots-and-38-or-39-tree-diagram-plots-by-madison-davis/

This is a Subpage to 

  • Genomics Volume 2, Results of Medical Text Analysis with Natural Language Processing (NLP) – PART B in NEW GENRE Series B, Volume 2

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

 

UPDATED on 6/23/2022

Series B, NEW GENRE Volumes 1,2 and Results of Medical Text Analysis with NLP

  • NEW GENRE Volume One: Genomics Orientations for Personalized Medicine – Series B, Volume 1
  • NEW GENRE Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology – Series B, Volume 2
  • Genomics Volume 2, Results of Medical Text Analysis with Natural Language Processing (NLP) – PART B in NEW GENRE Series B, Volume 2 This book has a Subpage: 

Genomics, Volume 2: NLP results – 38 or 39 Hypergraph Plots and 38 or 39 Tree diagram Plots by Madison Davis

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/genomics-volume-2-nlp-results-38-or-39-hypergraph-plots-and-38-or-39-tree-diagram-plots-by-madison-davis/

UPDATED on 6/7/2022

Series A, NEW GENRE Volumes 1,2,3,4,5,6

NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms – Series A: Volume 1

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-one-perspectives-on-nitric-oxide-in-disease-mechanisms-series-a-volume-1/

 

NEW GENRE Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: Series A, Volume 2

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-two-cardiovascular-original-research-cases-in-methodology-design-for-content-co-curation-series-a-volume-2/

 

NEW GENRE Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics – Series A, Volume 3

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-three-etiologies-of-cardiovascular-diseases-epigenetics-genetics-and-genomics-series-a-volume-3/

 

NEW GENRE Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-four-therapeutic-promise-cardiovascular-diseases-regenerative-translational-medicine-series-a-volume-4/

 

NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/

 

NEW GENRE Volume Six: Interventional Cardiology for Disease Diagnosis and and Cardiac Surgery for Condition Treatment – Series A, Volume 6

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-six-interventional-cardiology-for-disease-diagnosis-and-and-cardiac-surgery-for-condition-treatment-series-a-volume-6/

 

UPDATED on 6/6/2022

Audio English-Spanish: BioMed e-Series

  • NEW GENRE Audio English-Spanish – Series A: e-Books on Cardiovascular Diseases
  • NEW GENRE Audio English-Spanish – Series B: Frontiers in Genomics Research
  • NEW GENRE Audio English-Spanish – Series C: e-Books on Cancer & Oncology
  • NEW GENRE Audio English-Spanish – Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology
  • NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine  

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

UPDATED on 5/24/2022

  • 1.0 LPBI IP Asset Class I: Journal Articles by Top Authors

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2022/04/11/equity-sharing-calculation-a-scoring-system-for-authors-a-total-articles-single-author-and-multiple-authorsb-total-articles-views-and-c-authors-proportion-of-own-articles-views-in/

More details are found in

https://pharmaceuticalintelligence.com/2020/12/08/papers-citing-pharmaceuticalintelligence-com/

 

  • LinkedIn 1st degree connections by Biotech Company Name and by Connections positions

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025

and

Data Scientist, Research Assistant III: Tianzuo George Li

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

 

UPDATED on 5/7/2022

Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and All Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON

Real Time coverage: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2022/05/07/tweets-at-wmif2022-by-pharma_bi-aviva1950-and-all-retweets-of-these-tweets-2022-world-medical-innovation-forum-gene-cell-therapy-may-2-4-2022/

 

2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON

https://pharmaceuticalintelligence.com/2022/05/01/2022-world-medical-innovation-forum-gene-cell-therapy-may-2-4-2022-boston-in-person/

 

Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare

https://pharmaceuticalintelligence.com/2022/05/09/lessons-on-the-frontier-of-gene-cell-therapy-the-disruptive-dozen-12-gct-breakthroughs-that-are-revolutionizing-healthcare/

UPDATED on 4/25/2022

TODAY, TEN years ago we on 4/25/2012 we published our 1st article

TODAY, 4/25/2022 we have 6,135 articles

TODAY, we have 2,115,903 Views at all time

http://pharmaceuticalintelligence.com

 

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

https://pharmaceuticalintelligence.com/2022/04/25/we-celebrate-ten-years-of-excellence-lpbi-group-4-2012-4-2022/

 

2022 Update from LPBI Group | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

 

 

 

 

UPDATED on 4/6/2022

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025 and Data Scientist, Research Assistant III: Tianzuo George Li

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

 

UPDATED on 3/30/2022

Tweet Collection of 2022 EmTechDigital @MIT, March 29-30, 2022

Tweet Author: Aviva Lev-Ari, PhD, RN

Selective Tweet Retweets for The Technology Review: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2022/04/02/tweet-collection-of-2022-emtechdigital-mit-march-29-30-2022/

 

UPDATED on 3/21/2022

Agenda overview: EmTech Digital & AI 2022, March 29-30, 2022

https://event.technologyreview.com/emtech-digital-2022/agenda-overview

Aviva will cover EmTech Digital & AI 2022, March 29-30, 2022 in REAL TIME

  • on a PRESS PASS from MIT granted today.

Another e-Proceedings and Tweet Collection.

 

UPDATED on 3/12/2022

2022 Update from LPBI Group

Author & Curator: Aviva Lev-Ari, PhD, RN

2023 Update from LPBI Group

 

UPDATED on 3/3/2022

We are publishers of PharmaceuticalIntelligence.com  

February 3rd, 2022 
Total # of Scientific Article Views 2,089.759
Total # of Global Scientific Comments 7,932
Total # of Categories – Journal Ontology 743
Total # of Tags 10,653
Total # of Scientific Articles 6,112

Top Author

2/3/2022

Total Views by AUTHOR,

2012-2022
2012pharmaceutical – Aviva Lev-Ari 508,457
Larryhbern – Dr. Larry 373,618
Sjwilliamspa – Dr. Williams 72,513
Tildabarliya – Tilda BarLiya 69,934
Dr. Sudipta Saha – Dr. Saha 39,088
Dror Nir – Dr. Nir 38,314
Demet Sag Ph.D. CRA GCP 20,030
Ritusaxena – Dr. Saxena 17,330
Gail S Thornton – PhD(c) 18,112
Irina Robu, PhD 10,208

UPDATED on 2/8/2022

Announcing LPBI Group’s SCIENCE SIDE – Monthly Virtual Lecture Series on Zoom

Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications

Presentation of Several Inventions of AI in Medical Applications (1) Cancer (2) Ultrasound and

Potential Collaboration & funding needs

LECTURE TITLE on 2/15/2022 11AM EST

“Biosensors in Oncology and Prematurity“

the prototype of a novel sensor for the detection of prematurity (nothing to do with uterine contractions) Prematurity is 9.8/100 pregnancies in US and a $22b expense in the first year of life.

LECTURE TITLE on 3/15/2022 11AM EST

AI Based Screening  and in Silico Genomic Diagnoses of Congenital Anomalies in Early Pregnancy

UPDATED on 2/7/2022

Announcing New Addition to LPBI Group in dual capacity: EAW & External Scientific Relations:

Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications

https://pharmaceuticalintelligence.com/contributors-biographies/experts-authors-writers-eaws/shraga-rottem-m-d-d-sc-expert-author-writer-external-scientific-relations-on-ai-in-medical-applications/

 

UPDATED on 12/6/2022

We announce that Pranith Rekala had joined LPBI Group’s Medical Text Analysis with NLP – Mission #1

Pranith Rekala, Research Assistant 2, Medical Text Analysis using NLP (Genomics Content, Project #1; Cancer Content, Project #2) and Molecular Design with Synthetic Biology Software (Project #3).

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/pranith-rekala-research-assistant-2-medical-text-analysis-using-nlp-genomics-content-project-1-cancer-content-project-2-and-molecular-design-with-synthetic-biology-software-project-3/

 

UPDATED on 1/17/2022

Today we issued a Certificate in Medical Text Analysis to Danielle Smolyar who Joined LPBI Group on 8/15/2020.

We are working now on PART B – NLP for Cancer, Volume 1 – New Genre e-Series 

UPDATED on 1/12/2022

There are FOUR points I wish you to take home FROM the five-hour Global Zoom Monthly Board Meeting on

1/11/2022, 11AM EST – 4PM EST

POINT #1:

1 to 7, below represent Frontiers of Compute Technologies in multiple domains where 2.0 LPBI Group had developed and is developing Intellectual Property.

  1. We completed NLP on 2 major books – 4 are work-in-progress
  2. Spanish audio and text for eTOCs of 18 books in Medicine
  3. Books – 140,000 page download
  4. Blockchain infrastructure – under development – Journal’s Ontology data schema in Knowledge graph in proof of concept stage
  5. PROTACs with PRosettaC – Galectins Drug Discovery with synthetic biology software
  6. Auction molecules on the Blockchain IT as NFT
  7. Auction scientific curations articles on the Blockchain IT as NFT

POINT #2:

We had added to our esteemed group of External Business Relations:

Mr. Luis De La Cruz, Phoenix, AZ – BUSINESS EXECUTIVE, COMMUNITY ACTIVIST AND PHILANTHROPIST

  • We will jointly pursuing the following FOUR initiatives that will be mutual beneficial

Exploration of LPBI Group potential contributions to several goals:

INITIATIVE #1:

A Documentary Film on Life Sciences

  • We will schedule a BRAINSTORMING JOINT Zoom meeting to kick off IDEAS
  • LPBI Group brings to the table the following resources:
  • All IP Asset Classes of relevance to the Film https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/
  • LPBI Groups Available Podcasts

Type 1:       Podcasts about LPBI Group’s Scientists

·  Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-sudipta-saha-phd-interview-by-gail-s-thornton-phdc-narrators-voice-gail-s-thornton-phdc/

· Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

· Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-prof-marcus-w-feldman-phd-biology-department-stanford-university-interview-by-gail-s-thornton-phdc/

· Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/partners-in-health-and-biz-radio-interview-with-aviva-lev-ari-ph-d-r-n-stephen-williams-ph-d-and-irina-robu-ph-d-on-5-2019-on-topic-of-3d-medical-bioprinting-technology-a-revolution-in-med/

Type 2:        Podcasts of LPBI Group’s LIBRARY of 250 INTERVIEWS with Scientific Leaders

Archive for the ‘Interviews with Scientific Leaders’ Category

https://pharmaceuticalintelligence.com/category/interviews-with-scientific-leaders/

 

INITIATIVE #2:

Use of LPBI Group’s BioMed e-Series for Mission:Brain Foundation 

https://www.missionbrain.org/

Mr. Luis De La Cruz, is attempting to invite to our February 15, 2022, Dr. Alfredo Quinones, MD

 

 

  • Dr. Alfredo Quinones MD Mayo Clinic Nuevo – surgeon is the director is this project to share the values of an outreach program for underserved/ disadvantaged communities is the USA.
https://youtu.be/eGCs2LHPtXM
  • Dr Alfredo Quinones-Hinojosa – CNN interview (Short Version)
https://www.youtube.com/watch?v=tstfM-PBsNQ

·      Rhoda Goldman Health Lecture: Dr. Alfredo Quinones-Hinojosa

https://www.youtube.com/watch?v=22q7P6RIflk

 

INITIATIVE #3

  • Proposal development for presentation to C.S. in Mexico Transfer of Ownership of LPBI Portfolio of IP https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

ALL Members of our External Business Relations and our Leadership will work on this proposal

 

INITIATIVE #4

  • Spanish speaking countries – Market penetration for LPBI Group’s New Genre Scientific Books – Spanish eTOCs – 18 books in Medicine

A Meeting with Montero and GTO and Mr. De La Cruz

Marketing our NEW GENRE e-Series Books in SPANISH speaking countries

WE will be scheduling a Zoom Meeting with all the Parties

POINT #3:

Dr. Williams developed a methodology on HOW TO write Interpretation for NLP Results

  • It was applied on Cancer, Volume 1
  • It is been applied on Genomics Volume 2
  • It will be applied on Genomics, Volume 1
  • It will be applied on Cancer, Volume 2

POINT #4:

  • Please Watch the Podcasts by Steve Wolfram on NLP and Blockchain
  • Please Watch the Podcasts by Vitalik Buterin on Multiple Blockchains
https://pharmaceuticalintelligence.com/2-0-lpbi-calendar-of-zooms/

UPDATED on 1/9/2022

The following sources represent UPDATES on LPBI Group:

Slide deck as of 8/24/2021 – available

 

I published on our Journal:

• 2021 – A Year in Review

https://pharmaceuticalintelligence.com/2022/01/04/goal-attainment-scaling-record-2021-a-year-in-review/

I published on our Journal:

• Portfolio on Intellectual Property Assets:

2012-2020 – Ten IP Assets

2021-2025 – Four IP Assets

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

I published on our Journal:

2.0 LPBI: A Unique Organization

• Podcast and Text with graphs

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/
  • LPBI Group’s multiple technologies include the following:
  1. We completed NLP on 2 major books of ours – 4 other books are in NLP test analysis process – work-in-progress
  2. Spanish audio and text for eTOCs of 18 books in Medicine

https://lnkd.in/ekWGNqA

  1. Bi-Lingual Spanish-English of eTOCs of these 18 Books
  2. Editorials of each Book in English Audio
  3. Above 1,2,3,4 – are included in a New Genre of Scientific Books Launched
  4. Books in above URL in Blue enjoy – 140,000 page download
  5. Blockchain infrastructure – under development – Journal’s Ontology data schema in Knowledge graph fluree.com format is in proof of concept stage
  6. PROTACs with PRosettaC – Galectins Drug Discovery with synthetic biology software
  7. Auction molecules on the Blockchain IT as NFT
  8. Auction scientific curations articles on the Blockchain IT as NFT

1,5,7,8,9,10, above represent Frontiers of Compute Technologies in multiple domains where LPBI Group had developed and is developing IP.

UPDATED on 1/3/2022

Mission #1: Medical Text Analysis with Wolfram Language NLP

New Genre BioMed e-Series to include the following Book structure:

PART A: Book electronic Table of Contents (eTOCs) in Spanish: Audio Format and Bi-lingual eTOCs in Spanish-English: Text Format

PART B: (1) Results of Wolfram Language for Biological Sciences – Natural Language Processing (NLP), (2) Appendix: Code used for each plot, and (3) Interpretation of NLP Results by Domain Knowledge Expert

PART C: Original Book’s Editorials excerpt selections in English: Audio Format and Text

 

Text Analysis with NLP for the entire volume: Cancer Volume 1 was completed on 12/27/2021 by Satwik Sunnam

Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

On Amazon.com since 8/11/2015

Interpretation for NLP Results of Cancer, Volume 1 – is announced as Complete on 1/3/2022. Interpretation done by Dr. Williams

New Genre Book Template for Genomics, Volume 2, PART B: Text Analysis with NLP was completed by Madison Davis on 12/29/2021

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology On Amazon.com since 12/28/2019

https://www.amazon.com/dp/B08385KF87

Interpretation for NLP Results of Genomics, Volume 2 – started on 1/3/2022.

  • Domain knowledge Expert Interpretation is done by Dr. Williams for Parts 2,3,4,7,8
  • Domain knowledge Expert Interpretation is done by Prof. Feldman for Part 5
  • Domain knowledge Expert Interpretation is done by Aviva Lev-Ari, PhD, RN for Part 1

 

UPDATED on 1/2/2022

Medical Text Analysis with Wolfram Machine Learning (ML) and Natural Language Processing (NLP) for LPBI Group’s

Genomics, Volume 2

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

is as of 1/2/2022 COMPLETE 

  • The Book’s PART B is 244 pages without the forthcoming Plot interpretations
  • without PART A: eTOCs Spanish Audio and Bi-Lingual Text
  • without PART C: Editorials – English Text & Audio
  • We need a PREFACE for the New Genre of Scientific Books

———————-@@@@@@@@@@@@@———————-

 

2021

 

UPDATED on 12/3/2021

UPDATED on 10/22/2021

How LPBI Group plans to use the Spanish Translation of its BioMed e-Series:  Cover page of 18  e-Books and electronic Table of Contents of these e-Books?

https://lnkd.in/ekWGNqA

In November 2021 – I will start to convert the Spanish eTOCs to Sound files and will start to publish

LPBI Group’s

Medical eBooks New Genre Edition !!!!

  • Spanish in Audio format, 
  • Bi-Lingual Text, 
  • NLP, Results and Domain Knowledge Expert Interpretations, and
  • English Editorials in Audio format

Application of LPBI Group’s New Genre Edition of Medical Books:

Each Series: A, B, C, D, E – ONE Volume per Series – 5 volumes in Total

  • Series A: Six volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
  • Series B: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
  • Series C: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
  • Series D: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
  • Series E: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio

Each Volume: in each Series – 18 volumes in Total 

  • Part A: Bi-Lingual eTOCs,
  • Part B: NLP, Results and Domain Knowledge Expert Interpretations
  • Part C: Editorials English Audio

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

https://www.amazon.com/dp/B07MGSFDWR

https://www.amazon.com/dp/B07MKHDBHF

https://www.amazon.com/dp/B08385KF87

http://www.amazon.com/dp/B08VTFWVKM

I am so excited about the

Medical eBooks New Genre Edition !!!!

UPDATED on 10/16/2021 

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/madison-davis-research-assistant-1-text-analysis-initiative/

It is with the highest OWE that I have issued today

LPBI’s first Cerficicate in Medical Text Analysis for COMPLETION OF 18 Months of Academic Training, the Completion of NLP of an entire book 

GENOMICS VOLUME 2

Latest in Genomics Methodologies for Therapeutics:

Gene Editing, NGS & BioInformatics,

Simulations and the Genome Ontology

2019

Volume Two

https://www.amazon.com/dp/B08385KF87

Deep Learning NLP

performed by

MADISON DAVIS

Thank you very much for completion of Genomics Volume 2 – This is a COLLOSAL accomplishment.

Genomics, Volume 2 will be LPBI’s 1st e-Book in

LPBI’s NEW GENRE EDITION of Scientific Books with the following format

  • Part A: eTOCs in Spanish AUDIO and Bi-Lingual Spanish and English TEXT – Text Source: ORIGINAL Book
  • Part B: Deep Learning NLP by Madison Davis – Graphic Visualization
  • Part C: Editorials in English AUDIO – Text Source: ORIGINAL Book

AFTER we finish PART B, above, I am advising Madison:

  • to consider to start to work on Synthetic Biology Software for Molecular Design for Galectins 

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

  • Starting a NEW Internship leading to a New Certificate in Synthetic Biology Software for Molecular Design for Galectins

Detailed description to be found on each Internship page, below

  • Medical Text Analysis (Deep Learning NLP)
  • IS, IT, CS and Data Science Internship
  • Blockchain Knowledge Graph Database Design with Interface to Wolfram NLP
  • Finance Internship: Financial Modeling
  • Synthetic Biology Software for Drug Design in Glycobiology Internship
  • Journalism and Marketing Communications in Pharmaceutical Media

I am encouraging all INTERNS to complete their assignments

  • GET Certificate(s)
  • Move to Another Internship – ALL ARE TUITION FREE

UPDATED on 10/7/2021

Tweets and Re-Tweets of Tweets by @pharma_BI  @AVIVA1950 at 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021, #WMIF2021

https://pharmaceuticalintelligence.com/2021/10/07/tweets-and-re-tweets-of-tweets-by-pharma_biaviva1950-at-2021-virtual-world-medical-innovation-forum-mass-general-brigham-gene-and-cell-therapy-virtual-may-19-21-2021/

UPDATED on 10/4/2021

Tweets and Re-Tweets of Tweets by @pharma_BI  @AVIVA1950  at EmTech MIT 2021, #EmTechMIT, Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/10/04/tweets-and-re-tweets-of-tweets-by-pharma_bi-aviva1950-at-emtech-mit-2021-emtechmit-9-28-to-9-30-2021%ef%bf%bc/

UPDATED on 10/2/2021

LPBI covered in Real Time the Virtual MIT Technology Review’s flagship event, September 28-30, 2021 – EmTech MIT 2021

  • EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://event.technologyreview.com/emtech-mit-2021/agenda

https://pharmaceuticalintelligence.com/2021/09/28/leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

  • Day 1: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/09/28/leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

  • Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/09/29/emtech-mit-2021-day-2-leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

  • EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://pharmaceuticalintelligence.com/2021/09/30/day-3-leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/

UPDATED on 9/27/2021

First day for Satwik Sunnam, Research Assistant 3 in our Team LPBI India is 9/27/2021

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/satwik-sunnam-research-assistant-3/

Assignment 1: Replacement to Dr. Pati on Cancer Volume 1, Chapters: 7,8,9,10,11,12

  • Produce Hypergraph V1 – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
  • Produce Tree Diagram Plots – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12

Assignment 2: Replacement to Ms. Amandeep Kaur on Genomics Volume 1, Chapters: 1-21

  • Kaur completed Data preparation Chapters: 1,2,3,4,5 and 21
  • Your assignment #2 include:
  • Produce Data preparation for Chapters 6 -20
  • Produce Deep Learning NLP for Chapters 1 to 21.

UPDATED on 9/22/2021

On 9/20 LPBI had issued the following Certificates:

First Certificate issued in the domain of

Medical Text Analysis with Deep Learning Natural Language Processing

Recipient: Yash Choudhary

On 9/17/2020, LPBI issued the following three Certificates in the domain of

IS, IT and Data Science

for the following Contributions:

Recipients: Abhisar Anand and Srinivas Sriram

for their contribution to IT system solution design for Data Extraction of Article Views

Problem definition:

To extract the views for each of the 6,000+ articles for different time periods. Must be done in a time-efficient manner that retrieves the necessary data for LPBI.

Conceptual solution:

Create a multiple-step process that involves web scraping the data in multiple processes to enhance the speed of the extraction, and use data analysis libraries in Python to format the data in the correct format.

Code Implementation: https://pharmaceuticalintelligence.com/sop-web-stat/

Recipients: Ethan Coomber

For his contributions to Text To Sound conversion of 150 Interviews with Scientific Leaders and for Twitter Analytics on LPBI’s two Twitter handles: @pharma_BI @AVIVA1950

UPDATED ON 9/6/2021

A long weekend ahead of us. Lots of good things to look forward to.

  • Labor Day with all its meaning.
  • For my culture, the High Holidays.

Blessed to be healthy, very creative and very productive.

What is New at LPBI Group:

  1. We got this week all our 18 #booksin #medicinetranslated to #spanish
    • Cover Page
    • electronic Table of Contents
  2. We created the first products using Wolfram #deeplearning
    Natural Language Processing #nlp
  3. We made advances regarding launching a #blockchain#knowledge#graphdatabases for our
    • +6,080 scientific articles
    • 18 Books in Medicine (English and Spanish)
    • 100 e-Proceeding oh Top Tier Biotech Conferences
    • +6,000 Biological Images
  4. Completed +150 conversion Text to Sound #TTS, I.e., Podcasts of Interviews with Scientific Leaders
  5. Received the code for our Information System allowing for #data–#analytics#extractionof #articles #views per Year
    YES: +2MM Views – #bigdata 3.3 Giga Bytes !!!!
  6. Made strides in further defining our platform for #syntheticbiologyin #drugdiscovery

#biotech #research #language #datascience #translation #ai

So much GOODNESS in one week

UPDATED ON 9/5/2021

Milestones reached on 3Q 2021

  1. IT & Data Science Internship– LPBI gained the code to run Article Views by any date, 2012 – 2021 – Contributions by Srini and by Abhisar
  2. Text to Sound: 150 of the 270 Interviews with Scientific Leaders were converted to Podcasts – Contribution by Ethan
  3. Sign up agreement with SpeechKit– Text to Sound conversion for (a) $204 for 360 podcasts per year (b) Archive bulk conversion 20 cents per Podcast (c) Use API for Spanish Text to Spanish Sound
  4. ALL 18 BOOKS have a COVER PAGE and an eTOCs in Spanish – Montero competed its Contractand was paid by a Loan Aviva made to LPBI.  On 9/1/2021 wired the funds to cover the Invoice.
  5. Instructions by Madison for all INTERNS on Deep Learning NLPusing Yash’s code – is almost ready
  6. Proof-of-Concept for Cardiovascular text with Deep Learning NLP is ready by Yash using Adina’s Data preparation
  7. PowerPoint SLIDE DECK for 2.0 LPBIis Ready – Text by Aviva and PPT by Srini and Abhisar
  8. Completion of Internship Definition and Certificate Designon 9/2/2021 – Joint Work with Robin and Beth https://pharmaceuticalintelligence.com/certificate-1-year/
  9. LPBI India is seeking additional Leadership to Dr. Saha and additional INTERNS for (a) Medical Text Analysis using Wolfram Deep Learning NLP and (b) Synthetic Biology Software for Drug Discovery
  10. Synthetic Biology in Drug Discovery – Mission #4 for LPBI USA is Mission #2 for LPBI India: Updated by Dr. Williams on 8/20/2021. He will present on 9/14/2021. See update https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

UPDATED ON 8/31/2021

August 31, 2021 is a GREAT day for both organizations:

  • Montero, Language Services, Madrid for COMPLETION of the Spanish Translation of LPBI Group’s EIGHTEEN Books in Medicine: Books Page Cover and electronic Table of Contents (eTOCs) per Volume
  • LPBI Group, Boston for having the EIGHTEEN products of the Spanish Translation as agreed upon

This Spanish Translation serves our quest to

  • (1) have the opportunity to REACH to the Medical communities in Spanish speaking countries and to Spanish speaking physicians and allied health professionals in the US, and
  • (2) having the ability to re-Publish every book and every e-Seriesas a New Genre of Scientific Books in several new formats:

Series A, B, C, D, E – per each Series:

  • Never published before as eTOCs of all Volumes in a Series
  • Never published before in Spanish: Text or Audio
  • Never published before in English Audio

All volumes in each Series – Bi-Lingual and Audio eTOCs

Cover Page and electronic Table of Contents

  • Spanish & English Bi-Lingual eTOCs in Text – Today the FINAL products delivered
  • Spanish eTOCs Translation in Audio [Text to Sound]
  • English eTOCs in Audio [Text to Sound]

Per Volume for each of the 18 Books – New Genre of Scientific Books

  • Part A: Bi-Lingual eTOCs: Spanish Audio and English Audio
  • Part B: Results of Deep Learning Natural Language Processing with Domain Knowledge Expert Interpretation in [English text work-in-progress] and Spanish text to be translation of this English Text [Future Plan]
  • Part C: Book original Editorials in English Audio [Text to Sound]

UPDATED ON 8/16/2021

Proof-of-Concept yielded LPBI’s SOPs on Natural Language Processing – How we will use Deep Learning NOT Statistical NLP !!!!!!!!

  • Yash’s code.nb
  • Deep learning methods
  • 25 keywords
  • Code file: code.nb
  • pdf
  • pdf

UPDATED ON 8/7/2021

#1:

LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate Program in Financial Modeling

https://pharmaceuticalintelligence.com/2021/08/07/lpbi-group-announces-5th-academic-internship-as-a-verifiable-certificate-in-financial-modeling-econometrics-as-one-semester-or-as-one-year-program-open-to-undergraduate-and-mba-students/

These are the FOUR ACADEMIC INTERNSHIPS as verifiable Certificate Programs One year or One semester: Volunteer base

  1. NLP – Medical Text Analysishttps://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
  2. Synthetic Biology in Drug Discovery targeting Galectinshttps://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
  3. IT Projects and Administration of IP Asset Classes. we developed a Plan for SOPs for LPBI Group’s IT & Data Science Management Projects https://pharmaceuticalintelligence.com/2021/07/11/plan-for-sops-for-lpbi-groups-it-data-science-management-projects/Informations technology & systems of LPBI: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images. All the platforms: Authoring, publishing and portals. Business analytics for Internet platforms presence: Twitter Analytics +1,100 followers of two handles and LinkedIn ~8,000 1st degree connections of LPBI’s Founder, including +500 CEOs.
  4. BLOCKCHAIN Architecture Design: Interface to NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY. Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN. NLP-Blockchain IT Infrastructure is needed. The NLP inferences are part of a knowledge graph database In BurstIQ case is a LifeGraph – the larger architecture of the system functionality [the voice of Erich G., Chief Architect, LPBI Blockchain Mission #2].

#2:

LPBI and Linguamatics are schedule to meet with

  • LPBI’s and Linguamatics’ potential NEW two clients:
  • Director of Research at an HMO &
  • COO/CEO of a Healthcare INSURER on
  • August 18, 2021 at 3PM EST

#3:

LPBI’s GLOBAL Monthly Zoom Meeting is on August 10, 2021 at11AM EST to 4PM EST – Please ATTEND

Presentations by

  • Williams
  • ALL 2021 SUMMER INTERNS
  • Aviva
  • External Presenter TBA

AGENDA for August 10, 2021 at 11AM EST to 4PM EST

Link sent on 8/9 at 5PM and on Link REMINDER on 8/10 at 9AM

https://pharmaceuticalintelligence.com/calendar/

UPDATED ON 8/3/2021

LPBI Team in LPBI India include: 3,4,6,7,8,10,11

 

UPDATED ON 7/26/2021

We are excited to have new Interns coming onboard with inquisitive minds and motivation to learn new skills and invest in their careers by Experientional  learning methods.

LPBI Group runs FOUR MAJOR INTERNSHIPS: Volunteer base

  1. NLP – Medical Text Analysis
  2. Synthetic Biology in Drug Discovery targeting Galectins
  3. IT Project and Administration of IP Asset Classes: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images
  4. BLOCKCHAIN Architecture design: Interface of NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY.

Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN.

  • NLP-Blockchain IT Infrastructure is needed.
  • The NLP inferences are part of a graph database
  • In BurstIQ case is a LifeGraph – the larger architecture of the system functionality.

LPBI has you and your education goals in mind:

  • We Offer esteemed Affiliation, Mentorship by Scientists
  • NEW skills development in NLP, ML, AI applications to Medical Text Analysis
  • Skills in Synthetic Biology for Drug Discovery
  • References and Resume paragraph on accomplishments and goals during the INTERNSHIP
  • Opportunity to contribute to Publications and Podcasting
  • Explorations of opportunities in Life Sciences in the US

UPDATED ON 7/26/2021

LPBI’s VALUATION is the stream of INNOVATIONS to date while being DEBT free:

  1. 4/2012 – LPBI is the Launcher of Scientific Curation Methodology for the e-Scientific Publishing industry https://pharmaceuticalintelligence.com/As late as in 2016 no big publisher, i.e., Elsevier, John Wiley had curation-based publications: Journal, Books, e-Proceedings, Gallery of +6,000 Biological Images as an IP asset class
  • At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
  1. 6/2013 – LPBI was the Publisher of the 1ste-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
  2. 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine
  3. On Amazon.com on 7/2021 – e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads
  4. LPBI launched NLP in 1/2020. Linguamatics/IQVIA performed NLP on 33 articles and 20 Biological Images. RESULTS:  +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:
  • Gene-Disease
  • Gene-Drug
  • Disease-Drug
  • These results were presented to a Healthcare Insurer, SLC, UT on 7/13/2021
  1. LPBI and BurstIQ are architecting NOW the first NLP-Blockchain IT infrastructure in existence
  • Linguamatics did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER
  1. On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, ABI Lab and SBH Sciences, Inc., Natick, MA
  2. On 7/25/2021 – LPBI announced it will have the NEWLY to be published BioMed e-Books As ANEW Publishing GENRE of SCIENTIFIC BOOKS
    • Bi-Lingual eTOCs, English & Spanish with Montero Language Services, Madrid and Content promotion by GTO, Madrid
    • NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and Audio: Spanish and other
    • Original English Book – Only Editorials(Preface, Introductions, Summaries and Epilogue] because the Bi-Lingual part is the eTOCs of the e-Book
    • New architecture of MULTIMEDIA SCIENTIFIC e-Books

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

  1. Based on the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/we are building
  • Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up alliances: Alliances are Labor component and LPBI is Materials – 25% on top paid by the B2B customer
  • B2C on Blockchain will use the Price List.

UPDATED ON 7/19/2021

Official launch of LPBI India – Zoom meeting

On July 19, 2021 at 11AM EST

UPDATED AGENDA

 

Member Name

Geographical region in India

Or

Place of Birth in India if now

outside of India

Distance from New Delhi

LANGUAGES

Dr (Lt Col) Vivek Lal

Ambuja Nagar, Kodinar (Sasan-Gir) Gujarat.

1300 kms

English, Hindi

Yash Choudhary

Dewas (Madhya Pradesh)

800 kms

English, Hindi

Dr. Premalata Pati

Bhubaneswar, Odisha

1764 kms

English, Hindi, Odia

Dr. Sudipta Saha

Kolkata, West Bengal

1500 kms

English, Hindi, Bengali

Dr. Ajay Gupta

Place of birth: New Delhi

0

English, Hindi

Amandeep Kaur

Kolkata, West Bengal

1500 kms

English, Hindi, Punjabi, Bengali

Indraneel Ghosh

Vadodara, Gujarat

1025 kms

English, Hindi, Bengali, Marathi, Gujarati

Aditya Bahl

Lucknow, UP

500

English, Hindi, Punjabi

Srinivas Sriram

Place of Birth: Chennai, Tamil Nadu

2,187 kms

English, Tamil

Abhisar Anand

Place of Birth: Muzaffarpur, Bihar

1,042 kms

English, Hindi

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, MA

is Launching LPBI India on 7/19/2021

LPBI India Official Launch

on Zoom on July 19, 2021 at 11AM EST

  • I wish to invite you to attend this Zoom meeting using the Zoom Link, above

LPBI India LAUNCH

is on Monday July 19, 2021 at 11AM EST

Aviva – Founder 1.0 LPBI and 2.0 LPBI

  • Justifying the Launch of LPBI India todayis the Interaction between LPBI USAand LPBI India which is taking place multiple times every day
  • Senior level executive talent in India expressed interest to JOIN LPBI USA while living in India
  • It was Dr. Lal and Dr. Ghosh interest in joining LPBI USA that impacted Aviva’s Decision toward the Launch of LPBI India: Leadership + Professional Staff
  • Interactions among all members across Indiais mostly encouraged
  • We are preparing a MAP with all the locations in India of our VIRTUAL organization
  • We are a community of inclusion and excellence challenging and aspiring for expression and growth of the best of our abilities without borders and/or pre-determinants of any kind: age, race, religion or gender
  • Interactions with Alumni of LPBI USAis mostly encouraged – we are very proud of each of you,

Congratulatory Remarks, each presenter from their own perspective:

  1. LPBI USA Board member,  Marc W. Feldman, Stanford University [7/18/2021 – Medical Emergency] <<< – WE WISH YOU SPEEDY RECOVERY, next Global Zoom on August 10, 2021 – Congratulatory remarks will be delivered
  2. LPBI USA Board member,   Stephen J. Williams,Temple University
  3. Ajay Gupta of UC, Irvine, LPBI USA, External Scientific Relations
  4. Aditya Bahl, MBA, LPBI USA, External Business Relationsto LPBI USA since 1/2020. Mr. Bahl is ex-Novastis and ex-J&J, the Founding Director at RAS Life Science Solutions, based in Frankfurt, Germany
  5. Raphael Nir, Founder, ABI Lab and President, SBH, Inc in Natick, MA – We will have in 4Q’2021 a JOINTmeeting dedicated to Mission #2, below

  

Mission #1:

Medical Text Analysis with Natural Language Processing (NLP), Machine Learning (ML), Artificial Intelligence (AI)

 

The Medical Text includes FOUR corpuses of content created by the Team at LPBI USA since 4/2012:

  1. Scientific Curation Articles published in our Open Access Journal http://pharmaceuticalintelligence.com

N = +6,070, Views = +2Million, with an ontology of +730 categories of Research in the Life Sciences, Medicine, Pharmaceutics and Healthcare

  1. 18 e-Books in Medicine https://lnkd.in/ekWGNqA

128,000 page download on Amazon.com – Cover Pages and electronic Table of Contents (eTOCs) of the 18 books are been translated to Spanish in Madrid, now

  1. 100 e-Proceedings of Global Medical and Biotech Conferences generated in Real Time, 2013 – 2021 https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/
  2. +6,200 Biological Images with text legend in use by the +6,000 articles – in the Media Galleryof LPBI on WordPress.com cloud. Mission #1 has increased the number of Biological images from 5,100 to +6,200

At LPBI India, been considered for the Leadership function for Mission #1: Dr. Vivek Lal, MD

STRATEGIC PLAN for Mission #1

For scaling up the Text Analysis of these 3.3 Giga Bytes of data we are in alliance with Linguamatics/IQVIA, London https://www.linguamatics.com/what-text-mining-text-analytics-and-natural-language-processing

  • We jointly presented their NLP results on our content in oncology to a Top HMO/Healthcare Insurer in UT on July 13, 2021. We are invited for additional meetings with both organizations: the HMO and the Healthcare Insurer
  • LPBI USA developed a ten-phase Protocol for our own content been subjected to Medical Text Analysis with NLP, ML, AI using Wolfram language for BioSciences

https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/

  • LPBI India will be involved in all of the ten-phase Protocol in using NLP, ML, AI
  • LPBI is in alliance with BurstIQ, Denver, CO https://www.burstiq.com/for Blockchain design for a Transactions Network for Content monetization: B2B and B2C. That process involve Indexing and data migration. LPBI India will play a role in these tasks as well

 

Mission #2:

Applications of Synthetic Biology Software to Galectins for design of new drug molecules.

  • Collaboration with   Raphael Nir of ABI Lab and SBH, Inc in Natick, MA. We will have in 4Q’2021 a dedicated meeting on Mission #2.
  • LPBI India will play a role in these tasks, please review:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877766/

  • LPBI USA has interest in Synthetic Biology Software for Drug Discoveryand has two scientists with expertise in Galectins as therapeutic targets
  • Scientists love Synthetic Biology – designing drug molecules using Software – igem.org

https://igem.org/Software

A repository of open source software tools.

Community driven data exchange standards.

Specific software frameworks built explicitly for synthetic biology.

  • LPBI USA will have a DropBox Folder with all the Synthetic Biology Software accessible toLPBI India
  • Mentorship and training will be offered by LPBI USA

At LPBI India, been considered for the Leadership function for Mission #2: Dr. Indraneel Ghosh, PhD

STRATEGIC PLAN for Mission #2

  • We will have in 4Q’2021 a JOINT meeting between LPBI USA, LPBI India with   Raphael Nir of ABI Lab and SBH, Inc in Natick, MA on Mission #2.
  • A collaboration between Dr. Ghosh and Dr. Nir is expected

 

AGENDA

Zoom of LPBI INDIA Launch on Monday July 19, 2021 at 11AM EST

PRESENTATIONS

  • Stephen J. Williams,LPBI USA, Chief Scientific Officer and Board Member is with LPBI USA since 9/2012 will have presentations
  • Aviva will have presentations

Senior Level at LPBI India:

  • LPBI India TEAM Members BIO Presentations: Each of the members of LPBI Indiawill present their BIO in <5 minutes, starting with

Dr. Sudipta Saha, PhD Prof. at Amity University, New Delhi. Dr. Saha is with LPBI USA since 9/2012, Expert, Author and Co-Editor

http://www.amazon.com/dp/B08VTFWVKM

Available on Amazon.com since 2/2/2021

https://www.amazon.com/dp/B075CXHY1B

On Amazon.com since September 4, 2017

Dr. Vivek Lal, MD, COO, Ambujanagar Multi-specialty Hospital, Ambujanagar, Dist. Gir-Somnath, Gujarat, India.

  • Paper collaboration with Dr. Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN on 9/2013, article has ~15,000 e-Readers https://pharmaceuticalintelligence.com/2013/09/23/do-novel-anticoagulants-affect-the-ptinr-the-cases-of-xarelto-rivaroxaban-and-pradaxa-dabigatran/

Dr. Indraneel Ghosh, PhD – Weizmann Institute PhD, 2000-2007, Hebrew speaker

  • CV on LPBI USA Website – Work-in-Progress

https://pharmaceuticalintelligence.com/contributors-biographies/inventors-biologics/indraneel-ghosh-phd-inventor-biologics-lead-on-lpbi-india-synthetic-biology-drug-discovery-team/

Dr. Ajay Gupta of UC, Irvine, Scientific Advisor to LPBI USA, frequent presentation on LPBI’s SCIENCE SIDE – Global Monthly Zoom

  • Ten Minuteson on Clinical Trials for RAMATROBAN  – Opportunities for Collaboration between His Company in USA & LPBI India, Dr. Lal’s Hospital and other Hospitals in India

Ramatroban is a thromboxane receptor antagonist. It is also a DP₂ receptor antagonist. It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma. Wikipedia

ChemSpider ID: 110413

Molar mass: 416.47 g·mol−1

Formula: C21H21FN2O4S

Members of Technical Staff (MTS) at LPBI India & LPBI USA:

  • All LPBI India MTS currently working on Mission #1 and
  • All LPBI USA MTScurrently working on IT/Data Science Projects
    • will be invited to considered Mission #2.
  • An Up-to-date CV in Biological SciencesREQUIRES DEMONSTRATION of making contributions with mentorship in both areas: Mission #1 and Mission #2

LPBI India and LPBI USA MTS – BIO Presentations: PostDocs, Masters and Students will present their Bios in <4 minutes:

  • Pati,PostDoc. NLP – One year Academic Training
  • Kaur, MSc. NLP – One year Academic Training
  • Choudhary,Student IITK – Summent intern, 6/15/ – 8/15/2021
  • Sriram,Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
  • Anand, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
  • Ethan Coomber, Middlebury College, VT – Research Assistant 3, Text to Audio Conversion and Twitter Analytics
  • Vaishnavee Joshi, MSc – Joining LPBI India on 8/15/2021

Alumni of LPBI USA are invited to join us on Monday, July 19, 2021, 11AM EST

  • Probodh Kandala, PhD, Regulatory Affairs Manager @ IQVIA Biotech; Drug Development Leader, Expert, Author, Writer with scientific reporting articlesin multiple of LPBI e-Books, chiefly Cancer and Immunology
  • Ritu Saxena, PhD, Astellas Pharma US, Co-Editor, LPBI’s Series C, Volume 1 http://www.amazon.com/dp/B013RVYR2K
  • Aviral Vatsa, MD, NHS Education for Scotland, Co-Editor,LPBI’s Series A, Volume 1 http://www.amazon.com/dp/B00DINFFYC
  • Aashir Awan, Research Scientist, Bristol Myers Squibb, Expert, Author, Writer (EAW) for PharmaceuticalIntelligence.com
  • Anamika Sarkar,Regeneron, EAW at LPBI 2014-2016

Alumni of LPBI USA:  Please catch up with us, we thank you for your contributions made to LPBI USA

  • Please review our portfolio of Intellectual property of 10 Asset Classes in 2021 https://pharmaceuticalintelligence.com/2019-vista/
  • Please review our six strategies for 2021-2025https://pharmaceuticalintelligence.com/vision/

@@@@@@@@ ALL NEED TO PLAN TO ATTEND 7/21, 2021 – LPBI USA – BUSINESS SIDE

UPDATED ON 7/5/2021

ANNOUNCEMENT of NEW SUMMER INTERN in Medical Text Analysis with NLP – Cardiovascular Content – 2021 Summer Internship in NLP – LPBI India

Yash Choudhary, Research Assistant 3

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/yash-choudhary-research-assistant-3/

UPDATED ON 6/20/2021

ANNOUNCEMENT of NEW SUMMER INTERN

Ethan Coomber, Research Assistant III, Data Science and Podcast Library Development 

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/ethan-coomber-research-assistant-iii-data-science-and-podcast-library-development/

UPDATED ON 6/16/2021

ANNOUNCEMENT of TWO NEW SUMMER INTERNS who also plan to start in 9/2021 the LPBI 2021-2022 Academic Training in NLP for Medical Text Analysis

Abhisar Anand, Research Assistant I

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/abhisar-anand-research-assistant-i/

Srinivas Sriram, Research Assistant I

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/srinivas-sriram-research-assistant-i/

UPDATED ON 5/17/2021

LPBI management wants you to be PROUD about

  1. The Spanish Translation 18 volumes (Cover Pages, eTOCs all books)  – Alliance with Montero Language Services, Madrid, Spainand their’s Marketing Communication Agency for

1.1  Plans for Content Promotion in Spanish Speaking Countries

1.2  Other Marketing Communications needs of 2.0 LPBI

  1. NLP plan for IP Asset Classes I,II, III, V – Consideration of Alliance with Linguamatics/IQVIAfor Indexing of +6,000 articles 
  2. Blockchain Transaction Network for Content monetization system design for Digital Store in a Healthcare Digital Marketplace: B2B, B2C – Collaboration with BurstIQ
  3. Insurer Contactand Proof-of-Concept READY for joint Presentation with Linguamatics/IQVIA
  4. IB in NYC preparing Proposal for LPBI becoming their Client
  5. Working with few Sources to identify C-Suite new Members
  • New Management
  • New Ownership
  • New Company – incorporation as ‘C’

UPDATED ON 5/5/2021

One Pager for 2.0 LPBI Group

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 18 books have been downloaded ~135,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

  • Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
  • From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
  • From Open Access we will transition to Blockchain transaction networks.
  • From Digital Cloud-based biographies we will create audio and video Podcasts
  • From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships

Our Transformational transition is two dimensional:

  • Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia. Currently the Table of Contents of 18 books is being translated into Spanish for the 22 Countries speaking Spanish.
  • Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.

We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/

5/5/2021

LPBI Group’s Organizational Chart was updated on 5/5/2021

4/24/2021

REMINDER of important articles in our repository

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL.  Author and Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/thriving-at-the-survival-calls-during-careers-in-the-digital-age-an-age-like-no-other-also-known-as-digital/

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

4/14/2021

Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD

https://pharmaceuticalintelligence.com/2021/04/14/mechanism-of-thrombosis-with-astrazeneca-and-j-j-vaccines-expert-opinion-by-kate-chander-chiang-ajay-gupta-md/

2/26/2021

2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

Real Time coverage: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/02/26/2021-virtual-world-medical-innovation-forum-mass-general-brigham-gene-and-cell-therapy-virtual-may-19-21-2021/

2/16/2021

Announcing two new members of the Medical Text Analysis with Machine Learning

Premalata Pati, PhD, PostDoc in Biological Sciences, Medical Text Analysis with Machine Learning

https://pharmaceuticalintelligence.com/contributors-biographies/postdoctorants-computer-science-pharmaceutical-sciences-biological-sciences/premalata-pati-phd-postdoc-in-pharmaceutical-sciences-medical-text-analysis-with-machine-learning/

Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder

https://pharmaceuticalintelligence.com/contributors-biographies/associates/amandeep-kaur-bsc-msc-9exp-5-2021-research-associate-2-medical-text-analysis-and-it-infrastructure-python-coder/

2/12/2021

Need for Global Response to SARS-CoV-2 Viral Variants

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/02/12/need-for-global-response-to-sars-cov-2-viral-variants/

Rise of a trio of mutated viruses hints at an increase in transmissibility, speeding the virus’ leaps from one host to the next

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/02/01/rise-of-a-trio-of-mutated-viruses-hints-at-an-increase-in-transmissibility-speeding-the-virus-leaps-from-one-host-to-the-next/

2/8/2021

LIVE – 50th Annual Lewis S. Rosenstiel Award to Katalin Karikó and Drew Weissman for work on messenger RNA, modification of Nucleic Acids applied in the development of COVID-19 Vaccines

Reporter & Real Time Coverage on 2/8/2021:

  • Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

https://pharmaceuticalintelligence.com/2021/01/22/50th-annual-lewis-s-rosenstiel-award-to-katalin-kariko-and-drew-weissman-for-work-on-messenger-rna-modification-of-nucleic-acids-applied-in-the-development-of-covid-19-vaccines/

2/5/2021

Today Series D: Volume 4, LPBI’s #18 Volume is LIVE

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases and Endocrinology

 

VOLUME 1: Metabolic Genomics and Pharmaceutics.

(Series D: BioMedicine & Immunology) Kindle Edition

On Amazon.com since 7/21/2015

http://www.amazon.com/dp/B012BB0ZF0

VOLUME 2: Infectious Diseases and Therapeutics

and

VOLUME 3: The Immune System and Therapeutics

(Series D: BioMedicine & Immunology) Kindle Edition. On Amazon.com since September 4, 2017

https://www.amazon.com/dp/B075CXHY1B

VOLUME 4: Human Reproductive System, Genomic Endocrinology and Cancer Types

(Series D: BioMedicine & Immunology) Kindle Edition.

On Amazon.com since February 2, 2021

http://www.amazon.com/dp/B08VTFWVKM

 

2/3/2021

Check our podcasts

  • Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-sudipta-saha-phd-interview-by-gail-s-thornton-phdc-narrators-voice-gail-s-thornton-phdc/

  • Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

  • Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-prof-marcus-w-feldman-phd-biology-department-stanford-university-interview-by-gail-s-thornton-phdc/

  • Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc

https://pharmaceuticalintelligence.com/audio-podcasts/partners-in-health-and-biz-radio-interview-with-aviva-lev-ari-ph-d-r-n-stephen-williams-ph-d-and-irina-robu-ph-d-on-5-2019-on-topic-of-3d-medical-bioprinting-technology-a-revolution-in-med/

2/1/2021

Milestone achieved today:

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical 

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

Thought on the transition

One Possible Strategy for an Acquisition is via a SPAC

https://pharmaceuticalintelligence.com/2021/01/30/one-possible-strategy-for-an-acquisition-is-via-a-spac/

1/8/2021

PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views

Hanoch Lev-Ari, PhD and Aviva Lev-Ari, PhD, RN

Total number of articles viewed in any given year depends on:

  1. The overall Average Article-Viewing Profile (AAVP)
  2. The number of articles published in the year of interest, and in each one of the preceding years.

In statistics, the article viewing process is known as a “marked point process”: the time-instants of article publication are the events described by the point process, while the “mark” is the subsequent process of viewing each particular article, ongoing from the moment of publication into the future over many years. The article viewing process is assumed to be statistically-independent from the publication time-instants.

https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/

1/6/2021

2.0 LPBI Team Welcomes to our Medical Text Analysis Team

Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder

https://pharmaceuticalintelligence.com/contributors-biographies/associates/amandeep-kaur-bsc-msc-9exp-5-2021-research-associate-2-medical-text-analysis-and-it-infrastructure-python-coder/

 

REUTERS NEXT (Jan 11-14) kicks off 2021 by gathering global leaders and forward thinkers to reimagine solutions to the challenges the new year brings

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/01/06/reuters-next-jan-11-14-kicks-off-2021-by-gathering-global-leaders-and-forward-thinkers-to-reimagine-solutions-to-the-challenges-the-new-year-brings/

1/3/2021

Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/

Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/01/01/announcing-strategic-transition-from-1-0-lpbi-to-2-0-lpbi-on-1-1-2021-new-management-and-new-technical-opportunities/

1/1/2021

Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities

Author: Aviva Lev-Ari, PhD, RN

For your New Opportunity in 2021:

  • Management,
  • MarkComm and
  • Scientific/Technical

CONTACT

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

 

DESCRIPTION

https://pharmaceuticalintelligence.com/vision/

 

Announcement

Strategic Transition from 1.0 LPBI to 2.0 LPBI on

 1/1/2021

 

We have transitioned from

  • 1.0 LPBI was an electronic Scientific Publisher, 2012 – 2020

to

  • 2.0 LPBI a Medical Text Analysis (NLP-ML-AI) – SaaS and Content Monetization (Blockchain) – BaaS. A new company profile, 2021 – 2025

Our New NEEDS in Business Development and M&A – Pursue with results:

  • Equity Sharing based

Opportunities Map in the Acquisition Arena

Our New NEEDS in Marketing Communication, Media & PR – Produce new Digital mediums

  • Equity Sharing based
  1. The Announcement of 2.0 LPBI Launch
  2. NEW Website for 2.0 – Initiative #2
  3. Podcast – Strategy #4 – we wish to publish 2 Podcasts per quarter
  4. Planning Advertisement for Amazon Books using Amazon Advertising
  5. NEW documentation on Strategy #2 – Monetization of Journal Articles
  6. NEW documentation on Strategy #2 – Monetization of other IP Asset Classes
  7. NEW documentation on Strategy #1, #3, #6
  8. Reporting on developments in Strategy #5: Joint Ventures & Partnership

Our New Scientific/Technical Opportunities in Natural Language Processing (NLP), Machine Learning (ML) and Artificial Intelligence (AI)

 

Seeking 10 Students INTERNS for a major Medical Text Analysis using NLP, ML, AI

This is a ONE year VIRTUAL STUDENT INTERNSHIP for

  • Computer Science & Biological Sciences or
  • PreMed students
  • PostDocs will develop the interpretation for the hyper-graphs

This internship is not fee for service – but voluntary and offers

  • Mentorship by Scientists
  • Letter of recommendation
  • Opportunity to publish with lead authors
  • Hands on experience with software
  • Opportunities to present in corporate business meetings
  • Scientific Career guidance
  • Access to contacts in Academe and Industry

DESCRIPTION

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

https://pharmaceuticalintelligence.com/2021/01/01/announcing-strategic-transition-from-1-0-lpbi-to-2-0-lpbi-on-1-1-2021-new-management-and-new-technical-opportunities/

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,058 other subscribers

  • Recent Posts

    • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
    • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
    • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com January 10, 2026
    • The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
    • 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
    • Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026
    • 2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle” December 15, 2025
    • Marquee Followers 80% Healthcare Persons and Institutions for @AVIVA1950 and @Pharma_BI December 8, 2025

  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d